US5254463A
(en)
*
|
1981-09-18 |
1993-10-19 |
Genentech, Inc. |
Method for expression of bovine growth hormone
|
GB8308235D0
(en)
*
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
*
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4923805A
(en)
*
|
1983-11-02 |
1990-05-08 |
Integrated Genetics, Inc. |
Fsh
|
ATE169334T1
(de)
*
|
1983-11-02 |
1998-08-15 |
Applied Research Systems |
Herstellung heterodimirer menschlicher fruchtbarkeitshormone
|
US5639639A
(en)
*
|
1983-11-02 |
1997-06-17 |
Genzyme Corporation |
Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
|
US6455282B1
(en)
|
1983-11-02 |
2002-09-24 |
Genzyme Corporation |
Cells, vectors and methods for producing biologically active TSH
|
US4840896A
(en)
*
|
1983-11-02 |
1989-06-20 |
Integrated Genetics, Inc. |
Heteropolymeric protein
|
US7138505B1
(en)
|
1984-01-12 |
2006-11-21 |
Novartis Vaccines And Diagnostics, Inc. |
Factor VIII:C nucleic acid molecules
|
FR2565599B1
(fr)
*
|
1984-06-08 |
1989-08-25 |
Integrated Genetics Inc |
Sequence d'adnc codant pour la beta fsh porcine, vecteur la comprenant, beta fsh produite et son utilisation
|
US5489529A
(en)
*
|
1984-07-19 |
1996-02-06 |
De Boer; Herman A. |
DNA for expression of bovine growth hormone
|
EP0173494A3
(de)
*
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimäre Rezeptoren durch Verbindung und Expression von DNS
|
US5807715A
(en)
*
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
GB8422238D0
(en)
*
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
US6808901B1
(en)
*
|
1984-09-03 |
2004-10-26 |
Celltech R&D Limited |
Production of chimeric antibodies
|
US5187263A
(en)
*
|
1984-10-12 |
1993-02-16 |
Zymogenetics, Inc. |
Expression of biologically active PDGE analogs in eucaryotic cells
|
US5498600A
(en)
*
|
1984-10-12 |
1996-03-12 |
Zymogenetics, Inc. |
Biologically active mosaic proteins
|
EP0487116B1
(de)
*
|
1984-10-12 |
1999-12-29 |
ZymoGenetics, Inc. |
Von Blutplättchen abstammende biologisch aktive Analoga eines Wachstumsfaktors in eukaryotischen Zellen
|
DE3439843A1
(de)
*
|
1984-10-31 |
1986-04-30 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Plasmide zur erhoehten produktion von penicillin g-amidase
|
US5045633A
(en)
*
|
1985-02-25 |
1991-09-03 |
Zymogenetics, Inc. |
Expression of biologically active PDGF analogs in eucaryotic cells
|
US5169939A
(en)
*
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
US5576195A
(en)
*
|
1985-11-01 |
1996-11-19 |
Xoma Corporation |
Vectors with pectate lyase signal sequence
|
AU606320B2
(en)
*
|
1985-11-01 |
1991-02-07 |
International Genetic Engineering, Inc. |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US5618920A
(en)
*
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
FI98829C
(fi)
*
|
1986-01-27 |
1997-08-25 |
Chiron Corp |
Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
|
US5595886A
(en)
*
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
US5260203A
(en)
*
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US4946778A
(en)
*
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
EP0281604B1
(de)
*
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Bindungsmoleküle mit einzelpolypeptidkette
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
IL84285A
(en)
*
|
1986-10-27 |
1993-03-15 |
Int Genetic Engineering |
Chimeric antibody with specificity to human tumor antigen
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
*
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
ATE120761T1
(de)
*
|
1987-05-21 |
1995-04-15 |
Creative Biomolecules Inc |
Multifunktionelle proteine mit vorbestimmter zielsetzung.
|
US5258498A
(en)
*
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
US5091513A
(en)
*
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5132405A
(en)
*
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5981278A
(en)
*
|
1987-05-29 |
1999-11-09 |
Tanox, Inc. |
Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
|
US6657050B1
(en)
|
1987-05-29 |
2003-12-02 |
Tanox, Inc. |
Chimeric viral-neutralizing immunoglobulins
|
US5834599A
(en)
*
|
1987-05-29 |
1998-11-10 |
Tanox Biosystems, Inc. |
Immunoconjugates which neutralize HIV-1 infection
|
CA1341235C
(en)
*
|
1987-07-24 |
2001-05-22 |
Randy R. Robinson |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
US6710169B2
(en)
|
1987-10-02 |
2004-03-23 |
Genentech, Inc. |
Adheson variants
|
US5336603A
(en)
*
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
DE3744595A1
(de)
*
|
1987-12-31 |
1989-07-13 |
Andreas Dr Plueckthun |
Verfahren zur gentechnischen herstellung von antikoerpern
|
GB8800077D0
(en)
*
|
1988-01-05 |
1988-02-10 |
Ciba Geigy Ag |
Novel chimeric antibodies
|
EP0327797B1
(de)
*
|
1988-01-05 |
2003-09-03 |
Roche Diagnostics GmbH |
Verfahren zur Herstellung von Proteinen oder proteinhaltigen Genprodukten
|
US5843708A
(en)
*
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
US6018026A
(en)
*
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US6004781A
(en)
*
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
ES2092468T3
(es)
*
|
1988-01-22 |
1996-12-01 |
Zymogenetics Inc |
Metodos para producir analogos de receptores secretados.
|
US5846534A
(en)
*
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
AU3342689A
(en)
*
|
1988-03-24 |
1989-10-16 |
Igen Incorporated |
Luminescent chimeric proteins
|
US5372812A
(en)
*
|
1988-04-04 |
1994-12-13 |
The General Hospital Corporation |
Composition and method for acceleration of clot lysis
|
US5582862A
(en)
|
1988-04-04 |
1996-12-10 |
General Hospital Corporation |
Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
|
US4975369A
(en)
*
|
1988-04-21 |
1990-12-04 |
Eli Lilly And Company |
Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
|
US5609869A
(en)
*
|
1988-08-19 |
1997-03-11 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
US5811265A
(en)
*
|
1988-08-19 |
1998-09-22 |
The General Hospital Corporation |
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
|
EP0763543A2
(de)
|
1988-09-02 |
1997-03-19 |
The Rockefeller University |
Eine Methode für die Präparation eines inflammatorisches Cytokins (MIP-2) und diagnostische und therapeutische Applikationen für das Cytokin oder dessen Antikörper
|
DE68929167T2
(de)
|
1988-09-06 |
2000-11-16 |
Xoma Corp |
Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
|
KR0184860B1
(ko)
|
1988-11-11 |
1999-04-01 |
메디칼 리써어치 카운실 |
단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US20040049014A1
(en)
*
|
1988-12-28 |
2004-03-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6291161B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertiore
|
US6680192B1
(en)
|
1989-05-16 |
2004-01-20 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
US6969586B1
(en)
*
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291158B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US6291160B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
WO1990014443A1
(en)
*
|
1989-05-16 |
1990-11-29 |
Huse William D |
Co-expression of heteromeric receptors
|
US6291159B1
(en)
*
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
DE69007430T2
(de)
*
|
1989-06-19 |
1994-07-07 |
Akzo Nobel Nv |
Radioimmuntherapie unter alphapartikelausstrahlung.
|
US7247475B2
(en)
*
|
1989-07-28 |
2007-07-24 |
Wyeth |
Method for producing monoclonal antibodies
|
US6475787B1
(en)
|
1989-07-28 |
2002-11-05 |
Wyeth |
Method for producing monoclonal antibodies
|
US5580774A
(en)
*
|
1989-07-31 |
1996-12-03 |
Eli Lilly And Company |
Chimeric antibodies directed against a human glycoprotein antigen
|
CA2065010A1
(en)
*
|
1989-08-23 |
1991-02-24 |
Brian Seed |
Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
|
ATE194384T1
(de)
|
1989-09-12 |
2000-07-15 |
Hoffmann La Roche |
Tnf-bindende proteine
|
US5959177A
(en)
*
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6995014B1
(en)
|
1989-10-27 |
2006-02-07 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US7005560B1
(en)
|
1989-10-27 |
2006-02-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US5202422A
(en)
*
|
1989-10-27 |
1993-04-13 |
The Scripps Research Institute |
Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
|
US7037722B1
(en)
|
1989-10-27 |
2006-05-02 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
FR2655660B1
(fr)
*
|
1989-12-11 |
1992-03-20 |
Rhone Poulenc Sante |
Nouveaux polypeptides, sequences d'adn permettant leur expression, procede de preparation et leur utilisation.
|
US6750325B1
(en)
|
1989-12-21 |
2004-06-15 |
Celltech R&D Limited |
CD3 specific recombinant antibody
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP0528881A4
(en)
*
|
1990-04-24 |
1993-05-26 |
Stratagene |
Methods for phenotype creation from multiple gene populations
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
*
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9206318D0
(en)
*
|
1992-03-24 |
1992-05-06 |
Cambridge Antibody Tech |
Binding substances
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5595887A
(en)
*
|
1990-07-16 |
1997-01-21 |
Bionebraska, Inc. |
Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
|
US5871732A
(en)
*
|
1990-11-27 |
1999-02-16 |
Biogen, Inc. |
Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
|
US6403771B1
(en)
|
1991-02-19 |
2002-06-11 |
Actinium Pharmaceuticals, Limited |
Method and means for site directed therapy
|
US6492160B1
(en)
|
1991-05-15 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US5858657A
(en)
*
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
US5962255A
(en)
*
|
1992-03-24 |
1999-10-05 |
Cambridge Antibody Technology Limited |
Methods for producing recombinant vectors
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Tech |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
ES2206447T3
(es)
|
1991-06-14 |
2004-05-16 |
Genentech, Inc. |
Anticuerpo humanizado para heregulina.
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5756096A
(en)
*
|
1991-07-25 |
1998-05-26 |
Idec Pharmaceuticals Corporation |
Recombinant antibodies for human therapy
|
IE922437A1
(en)
*
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
US6136310A
(en)
*
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
EP0656367A1
(de)
|
1991-08-22 |
1995-06-07 |
Becton, Dickinson and Company |
Methoden und Zusammensetzungen zur Krebstherapie und zur Vorhersagbarkeit der Reaktionen auf diese Behandlung
|
US20070031409A1
(en)
*
|
1991-09-26 |
2007-02-08 |
Stichting Rega Vzw |
Recombinant DNA-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments
|
US6764681B2
(en)
*
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US6027725A
(en)
*
|
1991-11-25 |
2000-02-22 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
DK1024191T3
(da)
*
|
1991-12-02 |
2008-12-08 |
Medical Res Council |
Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
|
AU3326693A
(en)
*
|
1991-12-12 |
1993-07-19 |
Scripps Research Institute, The |
Bifunctional antithrombotic molecules and antithrombotic polypeptides
|
ES2202310T3
(es)
*
|
1991-12-13 |
2004-04-01 |
Xoma Corporation |
Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US5871734A
(en)
*
|
1992-01-13 |
1999-02-16 |
Biogen, Inc. |
Treatment for asthma with VLA-4 blocking agents
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
US5583031A
(en)
*
|
1992-02-06 |
1996-12-10 |
President And Fellows Of Harvard College |
Empty major histocompatibility class II heterodimers
|
US5932214A
(en)
*
|
1994-08-11 |
1999-08-03 |
Biogen, Inc. |
Treatment for inflammatory bowel disease with VLA-4 blockers
|
US5733743A
(en)
*
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
GB9215541D0
(en)
|
1992-07-22 |
1992-09-02 |
Celltech Ltd |
Protein expression system
|
CA2100709C
(en)
*
|
1992-07-27 |
2004-03-16 |
Maurits W. Geerlings |
Method and means for site directed therapy
|
US5437951A
(en)
*
|
1992-09-03 |
1995-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Self-assembling recombinant papillomavirus capsid proteins
|
US5639641A
(en)
*
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
GB9223377D0
(en)
|
1992-11-04 |
1992-12-23 |
Medarex Inc |
Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
|
AU5670194A
(en)
*
|
1992-11-20 |
1994-06-22 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
CA2153692C
(en)
*
|
1993-01-12 |
2011-11-08 |
Roy R. Lobb |
Recombinant anti-vla4 antibody molecules
|
ATE249838T1
(de)
*
|
1993-05-12 |
2003-10-15 |
Chiron Corp |
Konserviertes motiv der hepatitis c virus e2/ns1 region
|
GB2294267B
(en)
|
1993-06-03 |
1996-11-20 |
Therapeutic Antibodies Inc |
Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
|
US5827690A
(en)
*
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
WO1995024483A1
(en)
*
|
1994-03-08 |
1995-09-14 |
Scotgen Biopharmaceuticals, Inc. |
Recombinant humanized anti-fb5 antibodies
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
USRE39548E1
(en)
*
|
1994-06-17 |
2007-04-03 |
Celltech R&D Limited |
Interleukin-5 specific recombinant antibodies
|
GB9412230D0
(en)
*
|
1994-06-17 |
1994-08-10 |
Celltech Ltd |
Interleukin-5 specific recombiant antibodies
|
US6140075A
(en)
*
|
1994-07-25 |
2000-10-31 |
Monsanto Company |
Method for producing antibodies and protein toxins in plant cells
|
US6080560A
(en)
*
|
1994-07-25 |
2000-06-27 |
Monsanto Company |
Method for producing antibodies in plant cells
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
ATE306930T1
(de)
*
|
1994-08-12 |
2005-11-15 |
Immunomedics Inc |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US6017697A
(en)
|
1994-11-14 |
2000-01-25 |
Eli Lilly And Company |
Excitatory amino acid receptor protein and related nucleic acid compounds
|
US6258529B1
(en)
|
1994-12-01 |
2001-07-10 |
Oravax, Inc. |
PCR amplification of rearranged genomic variable regions of immunoglobulin genes
|
US20030086922A1
(en)
*
|
1994-12-02 |
2003-05-08 |
David B. Ring |
Method of promoting an immune response with a bispecific antibody
|
WO1996017941A2
(en)
*
|
1994-12-07 |
1996-06-13 |
Bionebraska, Inc. |
Production of c-terminal amidated peptides from recombinant protein constructs
|
US20030144483A1
(en)
*
|
1995-05-04 |
2003-07-31 |
Medarex, Inc. |
Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
CA2222231A1
(en)
|
1995-06-07 |
1996-12-19 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US7175847B1
(en)
*
|
1995-06-07 |
2007-02-13 |
Biogen Idec Inc. |
Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
|
US6113898A
(en)
*
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US7153508B2
(en)
*
|
1995-06-07 |
2006-12-26 |
Biogen Idec Inc. |
Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
|
US7368111B2
(en)
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
JPH09124509A
(ja)
*
|
1995-10-27 |
1997-05-13 |
Sumitomo Electric Ind Ltd |
肝炎治療剤
|
US6440418B1
(en)
*
|
1995-11-07 |
2002-08-27 |
Idec Pharmaceuticals Corporation |
Methods of treating autoimmune diseases with gp39-specific antibodies
|
US6001358A
(en)
*
|
1995-11-07 |
1999-12-14 |
Idec Pharmaceuticals Corporation |
Humanized antibodies to human gp39, compositions containing thereof
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
*
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
GB9610967D0
(en)
|
1996-05-24 |
1996-07-31 |
Cambridge Antibody Tech |
Specific binding members,materials and methods
|
US5961976A
(en)
*
|
1996-06-03 |
1999-10-05 |
United Biomedical, Inc. |
Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
|
JP4503706B2
(ja)
*
|
1996-06-07 |
2010-07-14 |
ポニアード ファーマシューティカルズ,インコーポレイティド |
グリコシル化が改質されたヒト化抗体
|
GB9712818D0
(en)
|
1996-07-08 |
1997-08-20 |
Cambridge Antibody Tech |
Labelling and selection of specific binding molecules
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
US6114506A
(en)
*
|
1996-09-20 |
2000-09-05 |
General Hospital Corporation |
Composition and method for enhancing fibrinolysis
|
US6420140B1
(en)
*
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US5977319A
(en)
*
|
1996-10-21 |
1999-11-02 |
Cambridge Antibody Technology Limited |
Specific binding members for estradiol; materials and methods
|
US6417337B1
(en)
|
1996-10-31 |
2002-07-09 |
The Dow Chemical Company |
High affinity humanized anti-CEA monoclonal antibodies
|
US6348581B1
(en)
|
1996-10-31 |
2002-02-19 |
The Dow Chemical Company |
High affinity humanized anti-TAG-72 monoclonalantibodies
|
JPH10150984A
(ja)
*
|
1996-11-19 |
1998-06-09 |
Hagiwara Yoshihide |
抗体分子の製造方法
|
ATE383430T1
(de)
*
|
1997-03-20 |
2008-01-15 |
Us Gov Health & Human Serv |
Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
|
US5914394A
(en)
*
|
1997-03-27 |
1999-06-22 |
Millenium Pharmaceuticals, Inc. |
Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
|
US5955355A
(en)
*
|
1997-03-27 |
1999-09-21 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5866412A
(en)
*
|
1997-03-27 |
1999-02-02 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5939316A
(en)
*
|
1997-03-27 |
1999-08-17 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
DE69840998D1
(de)
|
1997-04-30 |
2009-09-03 |
Twinstrand Therapeutics Inc |
Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
|
US6156546A
(en)
*
|
1997-05-16 |
2000-12-05 |
Washington State University Research Foundation |
Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
|
US6528271B1
(en)
*
|
1997-06-05 |
2003-03-04 |
Duke University |
Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
|
US7541151B2
(en)
|
1997-06-05 |
2009-06-02 |
Duke University |
Single-cell biosensor for the measurement of GPCR ligands in a test sample
|
US5891646A
(en)
*
|
1997-06-05 |
1999-04-06 |
Duke University |
Methods of assaying receptor activity and constructs useful in such methods
|
US7147854B2
(en)
*
|
1997-06-23 |
2006-12-12 |
Yes Biotech Laboratories Ltd. |
Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
|
US6103466A
(en)
*
|
1997-07-14 |
2000-08-15 |
University Of Liege |
Double-muscling in mammals
|
DE69841139D1
(de)
*
|
1997-07-14 |
2009-10-22 |
Univ Liege |
Mutationen im myostatingen steigern muskelmasse in säugetieren
|
US20070067859A1
(en)
*
|
1997-07-14 |
2007-03-22 |
Michel Georges |
Double-muscling in mammals
|
US7250505B1
(en)
|
1997-08-21 |
2007-07-31 |
Fred Hutchinson Cancer Research Center |
Isolation and expression of a disabled protein gene mDab1 and methods
|
US20030170794A1
(en)
*
|
1997-09-18 |
2003-09-11 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6756361B1
(en)
|
1997-10-14 |
2004-06-29 |
Nabi |
Enterococcus antigens and vaccines
|
WO1999020752A1
(en)
|
1997-10-21 |
1999-04-29 |
The University Court Of The University Of Glasgow |
JMY, A CO-ACTIVATOR FOR p300/CBP, NUCLEIC ACID ENCODING JMY AND USES THEREOF
|
CA2307846A1
(en)
|
1997-11-21 |
1999-06-03 |
Genset S.A. |
Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
BR9814912A
(pt)
|
1997-11-28 |
2000-10-03 |
Genset Sa |
Sequência genÈmica e polipeptìdeos de chlamydia trachomatis, fragmentos dos mesmos e usos dos mesmos, em particular para o diagnóstico, a prevenção e o tratamento de infecção
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US7790856B2
(en)
*
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
US20040176572A1
(en)
*
|
1998-03-16 |
2004-09-09 |
Freimer Nelson B. |
Methods of compositions for diagnosing and treating chromosome-18p related disorders
|
CA2323830A1
(en)
|
1998-03-16 |
1999-09-23 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for diagnosing and treating chromosome-18p related disorders
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US6197947B1
(en)
|
1998-06-01 |
2001-03-06 |
The Rockefeller University |
Translation initiation factor 4AIII and methods of use thereof
|
JP2000000097A
(ja)
*
|
1998-06-15 |
2000-01-07 |
Nippon Zoki Pharmaceut Co Ltd |
Nef結合蛋白質、該蛋白質をコードするDNA並びに該蛋白質に対するモノクローナル抗体
|
US6803448B1
(en)
*
|
1998-07-22 |
2004-10-12 |
Vanderbilt University |
GBS toxin receptor
|
US8609614B2
(en)
*
|
1998-07-22 |
2013-12-17 |
Vanderbilt University |
GBS toxin receptor compositions and methods of use
|
US6727349B1
(en)
|
1998-07-23 |
2004-04-27 |
Millennium Pharmaceuticals, Inc. |
Recombinant anti-CCR2 antibodies and methods of use therefor
|
US6696550B2
(en)
|
1998-07-23 |
2004-02-24 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
US6312689B1
(en)
|
1998-07-23 |
2001-11-06 |
Millennium Pharmaceuticals, Inc. |
Anti-CCR2 antibodies and methods of use therefor
|
EP1112084B2
(de)
|
1998-08-11 |
2012-04-25 |
Biogen Idec Inc. |
Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
|
EA005948B1
(ru)
*
|
1998-08-31 |
2005-08-25 |
Байоджен, Инк. |
Применение cd2-связывающего агента для избирательного снижения числа cd45ro-позитивных эффекторных т-лимфоцитов памяти в организме пациента
|
AU6394399A
(en)
*
|
1998-09-18 |
2000-04-10 |
Rockefeller University, The |
Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
|
US20010036647A1
(en)
*
|
1998-10-22 |
2001-11-01 |
Prabhakara V. Choudary |
Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
|
MY155913A
(en)
*
|
1998-11-09 |
2015-12-15 |
Biogen Inc |
Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants
|
WO2000027428A1
(en)
|
1998-11-09 |
2000-05-18 |
Idec Pharmaceuticals Corporation |
Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
|
US6773911B1
(en)
*
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
US6358703B1
(en)
|
1998-12-10 |
2002-03-19 |
Bayer Corporation |
Expression system for factor VIII
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
KR100856446B1
(ko)
|
1998-12-23 |
2008-09-04 |
화이자 인크. |
Ctla-4에 대한 인간 단일클론 항체
|
EP1159300A2
(de)
|
1999-02-12 |
2001-12-05 |
Genetics Institute, Inc. |
Humanisierte immunoglobuline gerichtet gegen b7 moleküle und behandlungsmethoden damit
|
US6972125B2
(en)
|
1999-02-12 |
2005-12-06 |
Genetics Institute, Llc |
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
US6531125B1
(en)
|
1999-03-02 |
2003-03-11 |
Twinstrand Therapeutics Inc. |
Antiviral ricin-like proteins
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
KR101222450B1
(ko)
|
1999-03-25 |
2013-01-16 |
애보트 게엠베하 운트 콤파니 카게 |
사람 il-12에 결합하는 사람 항체 및 이의 제조방법
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
ES2274781T3
(es)
|
1999-04-13 |
2007-06-01 |
Wilex Ag |
Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
|
US6492497B1
(en)
*
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
BR0010524A
(pt)
*
|
1999-05-14 |
2002-05-28 |
Imclone Systems Inc |
Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
|
CA2305716A1
(en)
|
1999-05-28 |
2000-11-28 |
University Of Guelph |
Method for assay of wbpm
|
US20040001826A1
(en)
*
|
1999-06-30 |
2004-01-01 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
FR2797402B1
(fr)
|
1999-07-15 |
2004-03-12 |
Biomerieux Stelhys |
Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
EP2829609A1
(de)
|
1999-08-24 |
2015-01-28 |
E. R. Squibb & Sons, L.L.C. |
Humane Antikörper gegen CTLA-4-Antikörper und Verwendungen davon
|
JP2004504003A
(ja)
|
1999-09-24 |
2004-02-12 |
モルフォゲン ファーマスーティカルズ インコーポレイテッド |
多能性胚様幹細胞、その組成物、方法および使用
|
US6346249B1
(en)
|
1999-10-22 |
2002-02-12 |
Ludwig Institute For Cancer Research |
Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
|
US6342587B1
(en)
|
1999-10-22 |
2002-01-29 |
Ludwig Institute For Cancer Research |
A33 antigen specific immunoglobulin products and uses thereof
|
WO2001034636A1
(en)
|
1999-11-05 |
2001-05-17 |
The General Hospital Corporation |
Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
DE60141938D1
(de)
|
2000-02-02 |
2010-06-10 |
Univ Vanderbilt |
Verfahren zur vorbeugung und linderung angiogener erkrankungen durch impfung mit dem rezeptor für gbs-toxin (cm101)
|
CA2399387C
(en)
|
2000-02-11 |
2015-11-03 |
Biogen, Inc. |
Heterologous polypeptide of the tnf family
|
WO2001062800A1
(en)
|
2000-02-24 |
2001-08-30 |
Eidgenössische Technische Hochschule Zürich |
Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
|
DE60121733T2
(de)
*
|
2000-02-24 |
2007-08-09 |
Philogen S.P.A. |
Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen
|
CN101708165A
(zh)
*
|
2000-03-24 |
2010-05-19 |
生物领域医疗公司 |
用于主动栓塞术的微球体
|
US20030212022A1
(en)
*
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
US20050043262A1
(en)
*
|
2000-03-29 |
2005-02-24 |
Weiss Robert H. |
Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
|
US20030144236A1
(en)
*
|
2000-03-29 |
2003-07-31 |
Weiss Robert H |
Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
|
EP1276849A4
(de)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
Albumin fusionsproteine
|
US20010046496A1
(en)
*
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
US6696620B2
(en)
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
EP2287191B1
(de)
|
2000-05-10 |
2016-10-12 |
Mayo Foundation For Medical Education And Research |
Menschliche igm-antikörper, welche die fähigkeit besitzen, den wiederaufbau der myelinstruktur zu induzieren und deren diagnostische und therapeutische anwendung im zentralen nervensystem
|
US6358733B1
(en)
*
|
2000-05-19 |
2002-03-19 |
Apolife, Inc. |
Expression of heterologous multi-domain proteins in yeast
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP1299542A2
(de)
*
|
2000-06-06 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Nichtagonistische antikörper gegen humanes gp39, zusammensetzungen und deren verwendungen
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
PT2275449T
(pt)
|
2000-06-16 |
2016-12-27 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
DE60137421D1
(de)
|
2000-06-29 |
2009-03-05 |
Abbott Lab |
Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
|
CA2417357A1
(en)
|
2000-08-08 |
2002-02-14 |
St. Jude Children's Research Hospital |
Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
|
JP2004527456A
(ja)
*
|
2000-08-09 |
2004-09-09 |
イムクローン システムズ インコーポレイティド |
Egf受容体拮抗剤による過増殖性の疾患の治療
|
KR100886276B1
(ko)
|
2000-08-11 |
2009-03-04 |
기린 파마 가부시끼가이샤 |
인산 대사, 칼슘 대사, 석회화 및 비타민 d 대사를조절하는 폴리펩티드 및 그것을 코딩하는 dna
|
WO2002013861A2
(en)
*
|
2000-08-11 |
2002-02-21 |
Favrille, Inc. |
Method and composition for altering a t cell mediated pathology
|
US6911204B2
(en)
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
US6803211B2
(en)
|
2000-08-25 |
2004-10-12 |
Pfizer Inc. |
Methods and compositions for diagnosing and treating disorders involving angiogenesis
|
EP1197550A3
(de)
*
|
2000-08-25 |
2002-11-20 |
Pfizer Products Inc. |
Methoden und Zusammensetzungen zur Diagnose unde Behandlung von Krankheiten an denen Angiogenese beteiligt ist
|
AU8847801A
(en)
|
2000-08-25 |
2002-03-04 |
Basf Plant Science Gmbh |
Plant polynucleotides encoding novel prenyl proteases
|
ATE373717T1
(de)
*
|
2000-09-12 |
2007-10-15 |
Univ Washington |
Pde8a und seine verwendung
|
GB0022978D0
(en)
|
2000-09-19 |
2000-11-01 |
Oxford Glycosciences Uk Ltd |
Detection of peptides
|
US6610472B1
(en)
*
|
2000-10-31 |
2003-08-26 |
Genetastix Corporation |
Assembly and screening of highly complex and fully human antibody repertoire in yeast
|
AU2002241556B2
(en)
*
|
2000-11-01 |
2007-07-19 |
Elusys Therapeutics, Inc. |
Method of producing bispecific molecules by protein trans-splicing
|
US20050136431A1
(en)
*
|
2000-11-03 |
2005-06-23 |
Oakley Robert H. |
Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
|
US7163800B2
(en)
*
|
2000-11-03 |
2007-01-16 |
Molecular Devices Corporation |
Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
|
US7018812B2
(en)
*
|
2000-11-03 |
2006-03-28 |
Duke University |
Modified G-protein coupled receptors
|
CN1306272C
(zh)
|
2000-11-17 |
2007-03-21 |
罗切斯特大学 |
筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
ATE544785T1
(de)
|
2000-12-05 |
2012-02-15 |
Alexion Pharma Inc |
Rationell entworfene antikörper
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
PE20020574A1
(es)
*
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
EP2341060B1
(de)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
US7279324B2
(en)
*
|
2001-01-23 |
2007-10-09 |
Duke University |
Nucleic acid encoding G-protein coupled receptor with modified DRY motif
|
WO2002086096A2
(en)
*
|
2001-01-23 |
2002-10-31 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
US20020192675A1
(en)
*
|
2001-02-02 |
2002-12-19 |
The University Of Rochester |
Methods of identifying regulator molecules
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10
|
AU2002250236A1
(en)
*
|
2001-03-02 |
2002-09-19 |
Medimmune, Inc. |
Cd2 antagonists for treatment of autoimmune or inflammatory disease
|
AU2002254132A1
(en)
*
|
2001-03-06 |
2002-09-19 |
Sierra Sciences, Inc. |
Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
|
WO2002072787A2
(en)
*
|
2001-03-13 |
2002-09-19 |
Sierra Sciences, Inc. |
Telomerase expression repressor proteins and methods of using the same
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
US8231878B2
(en)
*
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US20090081199A1
(en)
*
|
2001-03-20 |
2009-03-26 |
Bioxell S.P.A. |
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
DE60236646D1
(de)
|
2001-04-13 |
2010-07-22 |
Human Genome Sciences Inc |
Anti-VEGF-2 Antikörper
|
RU2316337C2
(ru)
|
2001-04-24 |
2008-02-10 |
Мерк Патент Гмбх |
КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
|
DE10121255A1
(de)
*
|
2001-04-30 |
2002-11-07 |
Switch Biotech Ag |
Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
|
US7256257B2
(en)
*
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
US6972324B2
(en)
*
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
JP2004535400A
(ja)
*
|
2001-05-22 |
2004-11-25 |
デューク ユニバーシティ |
転移阻害のための組成物及び方法
|
US20020197253A1
(en)
*
|
2001-05-22 |
2002-12-26 |
Cheek Dennis J. |
Compositions and methods for promoting or inhibiting NDPK
|
WO2002097033A2
(en)
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
GB0112844D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Psimei Pharmaceuticals Plc |
Neutron capture therapy
|
US7745398B2
(en)
*
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
AU2002345743A1
(en)
*
|
2001-06-21 |
2003-01-08 |
Sierra Sciences, Inc. |
Telomerase expression repressor proteins and methods of using the same
|
WO2003007800A2
(en)
|
2001-07-17 |
2003-01-30 |
The General Hospital Corporation |
Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
|
JP2005510249A
(ja)
|
2001-07-20 |
2005-04-21 |
ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション, インク. |
狂犬病に対するワクチン接種と中枢神経系における遺伝子治療のためのリン酸化部位において核蛋白質が変異した弱毒化狂犬病ウイルス
|
US7858095B2
(en)
*
|
2001-07-24 |
2010-12-28 |
Astellas Us Llc |
Method for treating or preventing sclerotic disorders using CD-2 binding agents
|
US20050075488A1
(en)
*
|
2001-07-26 |
2005-04-07 |
Bright Stuart Willis |
Interleukin-1 beta antibodies
|
LT1434871T
(lt)
|
2001-09-20 |
2017-04-10 |
Immunex Corporation |
Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
|
US20050053935A1
(en)
|
2001-10-01 |
2005-03-10 |
Fishman Mark C. |
Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
|
EP1438400B1
(de)
*
|
2001-10-01 |
2009-06-17 |
Dyax Corp. |
Mehrkettige eukaryontische display-vektoren und deren verwendungen
|
US20040151721A1
(en)
*
|
2001-10-19 |
2004-08-05 |
O'keefe Theresa |
Humanized anti-CCR2 antibodies and methods of use therefor
|
US7282205B2
(en)
|
2001-11-07 |
2007-10-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-hepatitis A virus antibodies
|
US20030113813A1
(en)
*
|
2001-11-15 |
2003-06-19 |
Heidaran Mohammad A. |
Methods and devices for the integrated discovery of cell culture environments
|
EP1542719A4
(de)
|
2001-12-05 |
2006-06-21 |
Baylor College Medicine |
Verfahren und zusammensetzungen zur steuerung der knochenbildung über modulation des sympathikotonus
|
GB0129105D0
(en)
|
2001-12-05 |
2002-01-23 |
Celltech R&D Ltd |
Expression control using variable intergenic sequences
|
ES2528384T3
(es)
|
2001-12-12 |
2015-02-09 |
The Government Of The United States Of America, As Represented By The Secretary Department Of Healt |
Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
|
GB0130543D0
(en)
|
2001-12-20 |
2002-02-06 |
Univ Cambridge Tech |
Human antibodies and their use
|
EP2277889B1
(de)
|
2001-12-21 |
2014-07-09 |
Human Genome Sciences, Inc. |
Fusionsproteine von Albumin und Interferon beta
|
ATE441666T1
(de)
|
2001-12-28 |
2009-09-15 |
Kyowa Hakko Kirin Co Ltd |
Antikírper gegen den fibroblastenwachstumsfaktor 23
|
US6578724B1
(en)
*
|
2001-12-29 |
2003-06-17 |
United States Can Company |
Connector for use in packaging aerosol containers
|
US7135174B2
(en)
*
|
2002-01-07 |
2006-11-14 |
Amgen Fremont, Inc. |
Antibodies directed to PDGFD and uses thereof
|
US20040009498A1
(en)
*
|
2002-01-14 |
2004-01-15 |
Diversa Corporation |
Chimeric antigen binding molecules and methods for making and using them
|
AU2003209340A1
(en)
*
|
2002-01-18 |
2003-09-02 |
Bristol-Myers Squibb Company |
Predictor sets for tyrosine kinase pathways
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
BRPI0308376B8
(pt)
|
2002-03-11 |
2021-05-25 |
Bayer Pharma Aktiengellschaft |
molécula de anticorpo anti-ed-b humana, seu uso e composição
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20030182669A1
(en)
*
|
2002-03-19 |
2003-09-25 |
Rockman Howard A. |
Phosphoinositide 3-kinase mediated inhibition of GPCRs
|
US20030233197A1
(en)
*
|
2002-03-19 |
2003-12-18 |
Padilla Carlos E. |
Discrete bayesian analysis of data
|
WO2003085093A2
(en)
*
|
2002-04-01 |
2003-10-16 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to gmad
|
GB0207533D0
(en)
|
2002-04-02 |
2002-05-08 |
Oxford Glycosciences Uk Ltd |
Protein
|
JP2005535572A
(ja)
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
組換え抗インターロイキン−9抗体
|
WO2003086459A1
(en)
*
|
2002-04-12 |
2003-10-23 |
Medarex, Inc. |
Methods of treatement using ctla-4 antibodies
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
AU2003221575B2
(en)
|
2002-05-02 |
2010-06-10 |
Dalia Barsyte |
Teneurin C-terminal associated peptides (TCAP) and uses thereof
|
WO2003100008A2
(en)
*
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Neutralizing human anti-igfr antibody
|
US7290215B2
(en)
*
|
2002-06-03 |
2007-10-30 |
Microsoft Corporation |
Dynamic wizard interface system and method
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
ES2368733T3
(es)
|
2002-07-18 |
2011-11-21 |
Merus B.V. |
Producción recombinante de mezclas de anticuerpos.
|
EP1525311A2
(de)
*
|
2002-07-19 |
2005-04-27 |
Cellzome Ag |
Proteinkomplexe des transkriptionellen aktivatorproteins tip60
|
AU2003267999B2
(en)
|
2002-07-19 |
2010-03-11 |
Abbvie Biotechnology Ltd |
Treatment of TNFalpha related disorders
|
EP1545613B9
(de)
|
2002-07-31 |
2012-01-25 |
Seattle Genetics, Inc. |
Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
|
EP1534335B9
(de)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
CA2492524A1
(en)
*
|
2002-08-15 |
2004-02-26 |
Epitomics, Inc. |
Humanized rabbit antibodies
|
CA2496272A1
(en)
|
2002-08-20 |
2004-03-04 |
Millennium Pharmaceuticals, Inc. |
Integrin b6 markers for compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
|
US20040265315A1
(en)
*
|
2002-09-05 |
2004-12-30 |
Christine Dingivan |
Methods of preventing or treating T cell malignancies by administering CD2 antagonists
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
CA2499081A1
(en)
*
|
2002-09-16 |
2004-04-22 |
Elusys Therapeutics, Inc. |
Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
|
US20040053363A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
US20040053359A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Thomas Ryll |
Method for production of a multimeric protein by cell fusion
|
JP2006516883A
(ja)
|
2002-09-19 |
2006-07-13 |
アメリカ合衆国 |
P.アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
|
US7514233B2
(en)
|
2002-09-26 |
2009-04-07 |
K.U. Leuven Research & Development |
Integrase cofactor
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
AU2003273921A1
(en)
*
|
2002-09-27 |
2004-04-19 |
Oridis Biomed Forschungs-Und Entwicklungs Gmbh |
Polypeptides and nucleic acids encoding these and their use for the prevention,diagnosis or treatment of liver disorders and epithelial cancer
|
US7541440B2
(en)
*
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
EP1551876B1
(de)
|
2002-10-16 |
2011-03-16 |
Purdue Pharma L.P. |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
US7485306B2
(en)
|
2002-10-29 |
2009-02-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Lutzomyia longipalpis polypeptides and methods of use
|
NZ540562A
(en)
|
2002-11-26 |
2008-04-30 |
Pdl Biopharma Inc |
Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
|
AU2003298816C1
(en)
|
2002-12-02 |
2010-12-16 |
Amgen Fremont, Inc. |
Antibodies directed to Tumor Necrosis Factor and uses thereof
|
JP4603894B2
(ja)
*
|
2002-12-03 |
2010-12-22 |
ユセベ ファルマ ソシエテ アノニム |
抗体産生細胞を同定するためのアッセイ
|
EP1581629B1
(de)
|
2002-12-06 |
2015-04-01 |
Millennium Pharmaceuticals, Inc. |
Verfahren zur identifizierung,beurteilung und behandlung von patienten mit einer proteasomen inhibitions therapie
|
AU2002953431A0
(en)
*
|
2002-12-19 |
2003-01-09 |
Murdoch University |
BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof
|
WO2004058171A2
(en)
|
2002-12-20 |
2004-07-15 |
Protein Design Labs, Inc. |
Antibodies against gpr64 and uses thereof
|
CA2886504C
(en)
|
2002-12-20 |
2019-01-08 |
Celera Corporation |
Wdr12 polymorphisms associated with myocardial infarction, methods of detection and uses thereof
|
EP2368578A1
(de)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
EP1585815A4
(de)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
|
EP1638587A4
(de)
|
2003-02-14 |
2007-04-18 |
Univ Missouri |
Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
WO2006113909A2
(en)
|
2005-04-19 |
2006-10-26 |
Seattle Genetics, Inc. |
Humanized anti-cd70 binding agents and uses thereof
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
DE10311248A1
(de)
*
|
2003-03-14 |
2004-09-30 |
Müller-Hermelink, Hans Konrad, Prof. Dr. |
Humaner monoklonaler Antikörper
|
PT2248899E
(pt)
|
2003-03-19 |
2015-09-23 |
Biogen Ma Inc |
Proteína de ligação do receptor nogo
|
AU2004224390A1
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
WO2004083865A2
(en)
|
2003-03-20 |
2004-09-30 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Materials and methods for modulating cell motility
|
KR101224235B1
(ko)
|
2003-04-11 |
2013-01-25 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
SE0301087D0
(sv)
|
2003-04-14 |
2003-04-14 |
Cartela Ab |
New monoclonal antibody
|
NZ542988A
(en)
|
2003-04-23 |
2008-07-31 |
Medarex Inc |
Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
|
AU2004234191A1
(en)
|
2003-04-30 |
2004-11-11 |
University Of Zurich |
Methods for treating cancer using an immunotoxin
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
HUE024996T2
(en)
|
2003-05-12 |
2016-01-28 |
Helion Biotech Aps |
Anti-MASP-2 antibodies
|
CA2525917C
(en)
|
2003-05-16 |
2017-07-04 |
Mayo Foundation For Medical Education & Research |
Compositions and methods including a recombinant human mab that promotes cns remyelination
|
CA2527694C
(en)
|
2003-05-30 |
2015-07-14 |
Hendricus Renerus Jacobus Mattheus Hoogenboom |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
GB0312481D0
(en)
|
2003-05-30 |
2003-07-09 |
Celltech R&D Ltd |
Antibodies
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
GB0313259D0
(en)
|
2003-06-09 |
2003-07-16 |
Consejo Superior Investigacion |
Magnetic nanoparticles
|
BRPI0411852A
(pt)
|
2003-06-27 |
2006-05-23 |
Abgenix Inc |
anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
|
GB0315450D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
WO2005010040A1
(en)
*
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
WO2005010163A2
(en)
*
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
|
EP1498133A1
(de)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Verwendung von pak-Inhibitoren zur Behandlung von Gelenkerkrankungen
|
US7727752B2
(en)
*
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
CA2445420A1
(en)
*
|
2003-07-29 |
2005-01-29 |
Invitrogen Corporation |
Kinase and phosphatase assays
|
US7619059B2
(en)
*
|
2003-07-29 |
2009-11-17 |
Life Technologies Corporation |
Bimolecular optical probes
|
WO2005012526A1
(en)
|
2003-08-04 |
2005-02-10 |
The Hospital For Sick Children |
Lafora's disease gene
|
EP1651276A4
(de)
*
|
2003-08-08 |
2009-05-06 |
Barnes Jewish Hospital |
Emulsionspartikel für die abbildung und therapie und verwendungsverfahren dafür
|
CA2534661A1
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
ES2291917T3
(es)
*
|
2003-09-05 |
2008-03-01 |
Cellzome Ag |
Tratamiento de enfermedades neurodegenerativas.
|
EP1514561A1
(de)
|
2003-09-10 |
2005-03-16 |
Philogen S.p.A. |
Tumorvaskulatur Zielrichtung mittels Verwendung eines gegen Fibronectin ED-B radiomarkierten Antikörpers L19
|
CA2539490A1
(en)
|
2003-09-18 |
2005-03-24 |
Genmab A/S |
Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
|
ES2453895T3
(es)
*
|
2003-09-23 |
2014-04-08 |
University Of North Carolina At Chapel Hill |
Células que expresan vitamina K epóxido reductasa y uso de las mismas
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
EP1670350A4
(de)
|
2003-10-07 |
2008-02-13 |
Millennium Pharm Inc |
Nukleinsäuremoleküle und proteine für die identifizierung, beurteilung, prävention und behandlung von ovarialkrebs
|
EP1673450B1
(de)
|
2003-10-14 |
2010-04-28 |
Baxter International Inc. |
Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
|
WO2005037313A2
(en)
|
2003-10-17 |
2005-04-28 |
University Court Of The University Of Edinburgh |
Tissue repair by modulation of beta-1 integrin biological function
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
US20050214805A1
(en)
*
|
2003-11-10 |
2005-09-29 |
Q-Rna, Inc. |
Methods of detection employing immuno-Q-Amp technology
|
PE20090047A1
(es)
|
2003-11-10 |
2009-01-26 |
Schering Corp |
Anticuerpo recombinante humanizado anti-interleuquina 10
|
US20060199194A1
(en)
*
|
2003-11-10 |
2006-09-07 |
Q-Rna, Inc. |
Methods of detection using immuno-Q-Amp technology
|
EP1687066B1
(de)
|
2003-11-14 |
2012-08-29 |
Brigham and Women's Hospital, Inc. |
Verfahren zur modulation der immunität
|
CA3050151C
(en)
|
2003-11-26 |
2023-03-07 |
Celera Corporation |
Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
|
JP2007521248A
(ja)
|
2003-12-10 |
2007-08-02 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
ヒト化抗ccr2抗体および該抗体を使用する方法
|
US7427670B2
(en)
*
|
2003-12-19 |
2008-09-23 |
Cytochroma Inc. |
Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
JP4943161B2
(ja)
|
2003-12-23 |
2012-05-30 |
ジェネンテック, インコーポレイテッド |
新規抗il13モノクローナル抗体での癌の処置
|
DK1704166T3
(en)
|
2004-01-07 |
2015-06-01 |
Novartis Vaccines & Diagnostic |
M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
|
EP1737971B1
(de)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Gemische bindender proteine
|
CN1925869A
(zh)
*
|
2004-01-29 |
2007-03-07 |
塞尔卓姆股份公司 |
使用gpr49治疗神经变性疾病
|
ES2300852T3
(es)
*
|
2004-01-29 |
2008-06-16 |
Cellzome Ag |
Tratamiento de enfermedades neurogenerativas mediante el uso de gpr49.
|
CA2555144A1
(en)
*
|
2004-02-06 |
2005-08-25 |
Astellas Us Llc |
Methods of treating skin disorders
|
BRPI0507026A
(pt)
|
2004-02-09 |
2007-04-17 |
Human Genome Sciences Inc |
proteìnas de fusão de albumina
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
AU2005224081B2
(en)
|
2004-03-12 |
2011-06-30 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
ES2387809T3
(es)
*
|
2004-03-19 |
2012-10-02 |
Imclone Llc |
Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
|
EP2053062A1
(de)
*
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobinvarianten außerhalb der Fc-Region
|
US7973139B2
(en)
*
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
DE602004025291D1
(de)
*
|
2004-03-26 |
2010-03-11 |
Cellzome Ag |
Behandlung von neurodegenerativen erkrankungen durch verwendung von laptm4b
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
US7794713B2
(en)
*
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20080038265A1
(en)
*
|
2004-04-09 |
2008-02-14 |
Reilly Edward B |
Antibodies to Erythropoietin Receptor and Uses Thereof
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
US20060018902A1
(en)
*
|
2004-04-09 |
2006-01-26 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
US20050227289A1
(en)
|
2004-04-09 |
2005-10-13 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
WO2005103086A1
(en)
|
2004-04-23 |
2005-11-03 |
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
JP4836942B2
(ja)
*
|
2004-04-30 |
2011-12-14 |
コーセラ, インコーポレイテッド |
リラキシンの調節による胎仔の発育の制御のための方法および組成物
|
BRPI0510691A
(pt)
*
|
2004-05-04 |
2007-12-26 |
Genaissance Pharmaceuticals |
marcadores de haplótipos e métodos de uso dos mesmos para determinar resposta ao tratamento
|
EP1745154B1
(de)
|
2004-05-07 |
2012-08-01 |
Celera Corporation |
Genetische polymorphismen assoziiert mit leberfibrose, verfahren zur detektion und verwendung davon
|
WO2005115436A1
(en)
*
|
2004-05-07 |
2005-12-08 |
Astellas Us Llc |
Soluble lfa-3 polypeptide for treating viral disorders
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
GB0412973D0
(en)
*
|
2004-06-10 |
2004-07-14 |
Celltech R&D Ltd |
Identification of antibody producing cells
|
WO2005123048A2
(en)
|
2004-06-21 |
2005-12-29 |
Proteome Sciences Plc |
Screening methods using c-abl, fyn and syk in combination with tau protein
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
ES2395094T3
(es)
|
2004-06-24 |
2013-02-08 |
Biogen Idec Ma Inc. |
Tratamiento de afecciones que implican la desmielinización
|
PL2287195T3
(pl)
|
2004-07-01 |
2019-10-31 |
Novo Nordisk As |
Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
CA2573821A1
(en)
|
2004-07-16 |
2006-01-26 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
CA2575190A1
(en)
*
|
2004-08-09 |
2006-02-16 |
Cellzome Ag |
Treatment of neurodegenerative diseases by the use of scd4 inhibitors
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
US7335491B2
(en)
|
2004-08-27 |
2008-02-26 |
Wyeth Research Ireland Limited |
Production of anti-abeta
|
US7300773B2
(en)
*
|
2004-08-27 |
2007-11-27 |
Wyeth Research Ireland Limited |
Production of TNFR-Ig
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
CN101010427B
(zh)
|
2004-09-06 |
2011-07-27 |
协和发酵麒麟株式会社 |
抗a33抗体
|
US7432359B2
(en)
|
2004-09-06 |
2008-10-07 |
Kirin Pharma Kabushiki Kaisha |
Anti-A33 antibody
|
JP2008518586A
(ja)
*
|
2004-09-09 |
2008-06-05 |
ユニバーシティ オブ ワシントン |
オールトランスレチノールすなわちオールトランス13,14−ジヒドロレチノールサチュラーゼ及びその使用方法
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
EP3073267A1
(de)
|
2004-09-21 |
2016-09-28 |
Medimmune, Inc. |
Antikörper gegen und verfahren zur herstellung von impfstoffen für respiratorische synzytialvirus
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
KR101370253B1
(ko)
*
|
2004-10-22 |
2014-03-05 |
암젠 인크 |
재조합 항체의 재접힘 방법
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
EP1814918A1
(de)
*
|
2004-10-29 |
2007-08-08 |
Elusys Therapeutics, Inc. |
Verwendung von cr1-bindenden molekülen bei der clearance und der induktion von immunreaktionen
|
US7709208B2
(en)
*
|
2004-11-08 |
2010-05-04 |
New York University |
Methods for diagnosis of major depressive disorder
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
DE602005014665D1
(de)
|
2004-11-09 |
2009-07-09 |
Philogen Spa |
Antikörper gegen tenascin-c
|
CN102746404B
(zh)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8288352B2
(en)
|
2004-11-12 |
2012-10-16 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
WO2006055638A2
(en)
|
2004-11-17 |
2006-05-26 |
Abgenix, Inc. |
Fully human monoclonal antibodies to il-13
|
EP1812064A4
(de)
|
2004-11-19 |
2009-07-08 |
Cornell Res Foundation Inc |
Verwendung vaskulärer endothelwachstumsfaktor-rezeptor-1+-zellen bei der behandlung und überwachung von krebs und beim screening bei chemotherapie
|
AU2005306399B2
(en)
*
|
2004-11-19 |
2012-02-09 |
Biogen Ma Inc. |
Treatment for multiple sclerosis
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
WO2006060419A2
(en)
|
2004-12-03 |
2006-06-08 |
Schering Corporation |
Biomarkers for pre-selection of patients for anti-igf1r therapy
|
WO2006061723A2
(en)
|
2004-12-06 |
2006-06-15 |
Kirin Beer Kabushiki Kaisha |
Human monoclonal antibodies to influenza m2 protein and methods of making and using same
|
TW200636066A
(en)
*
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized antibodies that recognize beta amyloid peptide
|
PE20061401A1
(es)
*
|
2004-12-15 |
2006-12-23 |
Neuralab Ltd |
ANTICUERPOS Aß PARA MEJORAR LA COGNICION
|
TW200635607A
(en)
*
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized Aβ antibodies for use in improving cognition
|
ATE504602T1
(de)
|
2004-12-20 |
2011-04-15 |
Amgen Fremont Inc |
Für humane matriptase spezifische bindungsproteine
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
ES2732623T3
(es)
|
2005-01-06 |
2019-11-25 |
Innate Pharma Sa |
Tratamientos y métodos de combinación anti-KIR
|
CN104829720B
(zh)
|
2005-01-06 |
2019-01-01 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
WO2006076594A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
EP2520669A3
(de)
|
2005-02-07 |
2013-02-27 |
GeneNews Inc. |
Biomarker für milde Arthrose und Verwendungen davon
|
BRPI0607639B1
(pt)
|
2005-02-08 |
2022-04-05 |
Genzyme Corporation |
Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
JP2008531730A
(ja)
*
|
2005-03-04 |
2008-08-14 |
キュアーディーエム、インク. |
I型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
|
EP1861711B1
(de)
|
2005-03-11 |
2012-01-11 |
Sanofi |
Verwendung von mgc4504
|
WO2006099365A2
(en)
|
2005-03-11 |
2006-09-21 |
Applera Corporation |
Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
|
CA2601574C
(en)
*
|
2005-03-15 |
2014-12-02 |
University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin k-dependent proteins
|
EP2384767B1
(de)
|
2005-03-24 |
2016-03-09 |
Millennium Pharmaceuticals, Inc. |
OV064-bindende Antikörper und Verfahren zu deren Verwendung
|
EP1866339B8
(de)
|
2005-03-25 |
2021-12-01 |
GITR, Inc. |
Gitr-bindende moleküle und ihre verwendung
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
CA2605024C
(en)
|
2005-04-15 |
2018-05-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
WO2008157379A2
(en)
|
2007-06-21 |
2008-12-24 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
BRPI0608096A2
(pt)
|
2005-04-26 |
2009-11-10 |
Pfizer |
anticorpos p-caderina
|
US8226926B2
(en)
|
2005-05-09 |
2012-07-24 |
Biosphere Medical, S.A. |
Compositions and methods using microspheres and non-ionic contrast agents
|
JP2008539742A
(ja)
*
|
2005-05-11 |
2008-11-20 |
サノフィ−アベンティス |
Gipプロモーター多型の使用
|
WO2006119983A2
(en)
|
2005-05-12 |
2006-11-16 |
Novartis Ag |
Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
|
NZ591701A
(en)
|
2005-05-16 |
2012-11-30 |
Abbott Biotech Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
US7393919B2
(en)
*
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
WO2006138429A2
(en)
|
2005-06-16 |
2006-12-28 |
The Feinstein Institute For Medical Research |
Antibodies against hmgb1 and fragments thereof
|
EP2937360A1
(de)
|
2005-06-17 |
2015-10-28 |
Merck Sharp & Dohme Corp. |
Ilt3-bindende moleküle und verwendungen davon
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
US7700739B2
(en)
*
|
2005-06-30 |
2010-04-20 |
Abbott Laboratories |
IL-12/p40 binding proteins
|
WO2007008848A2
(en)
*
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
CA2614436C
(en)
|
2005-07-07 |
2016-05-17 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
US7482124B2
(en)
*
|
2005-07-08 |
2009-01-27 |
Bristol-Myers Squibb Company |
Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
|
MX2008000253A
(es)
|
2005-07-08 |
2008-04-02 |
Biogen Idec Inc |
Anticuerpos de sp35 y usos de los mismos.
|
AU2006269940C1
(en)
|
2005-07-18 |
2013-11-07 |
Seagen Inc. |
Beta-glucuronide-linker drug conjugates
|
EP2388277A3
(de)
|
2005-07-18 |
2013-03-20 |
Amgen, Inc |
Humane Anti-B7RP1-neutralisierende Antikörper
|
JP5457671B2
(ja)
|
2005-07-28 |
2014-04-02 |
ノバルティス アーゲー |
M−csf特異的モノクローナル抗体およびその使用
|
SI2573114T1
(sl)
|
2005-08-10 |
2016-08-31 |
Macrogenics, Inc. |
Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
WO2007027906A2
(en)
*
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
EP1931710B1
(de)
|
2005-08-31 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Konstruierte anti-il-23-antikörper
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
EP3031470A3
(de)
|
2005-09-09 |
2016-08-10 |
The Johns Hopkins University |
Manipulation der regulatorischen t-zell- und dc-funktion durch targeting des neuritin-gens mit antikörpern, agonisten und antagonisten
|
WO2007037910A2
(en)
|
2005-09-14 |
2007-04-05 |
Fred Hutchinson Cancer Research Center |
Specific removal of activated immune cells
|
US7799530B2
(en)
|
2005-09-23 |
2010-09-21 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
US8906864B2
(en)
*
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
EP1931709B1
(de)
*
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc-varianten mit optimierten rezeptorbindungseigenschaften
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
UA92504C2
(en)
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
DE102005048898A1
(de)
*
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
KR20080068089A
(ko)
*
|
2005-10-21 |
2008-07-22 |
지티씨바이오쎄라퓨틱스,인크. |
항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
|
ATE518007T1
(de)
|
2005-10-21 |
2011-08-15 |
Genenews Inc |
Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
|
PE20070796A1
(es)
*
|
2005-10-24 |
2007-08-15 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
US20090074720A1
(en)
*
|
2005-10-28 |
2009-03-19 |
Sabbadini Roger A |
Methods for decreasing immune response and treating immune conditions
|
WO2007049770A1
(ja)
|
2005-10-28 |
2007-05-03 |
Meiji Seika Kaisha, Ltd. |
緑膿菌の外膜タンパク質pa5158
|
US20080213274A1
(en)
*
|
2005-10-28 |
2008-09-04 |
Sabbadini Roger A |
Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
|
EP1948235B1
(de)
|
2005-11-01 |
2013-08-28 |
AbbVie Biotechnology Ltd |
Methoden zur bestimmung der wirksamkeit von adalimumab bei patienten mit morbus bechterew mit ctx-ii und mmp3 als biomarker
|
PL2500030T5
(pl)
|
2005-11-04 |
2019-02-28 |
Genentech, Inc. |
Zastosowanie inhibitorów drogi aktywacji dopełniacza w leczeniu chorób oczu
|
MX2008005764A
(es)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
|
US7939069B2
(en)
|
2005-11-09 |
2011-05-10 |
Abbott Laboratories |
Human BNP immunospecific antibodies
|
JP5364378B2
(ja)
*
|
2005-11-09 |
2013-12-11 |
アボット・ラボラトリーズ |
ヒトbnp免疫特異的抗体
|
JP2009515897A
(ja)
|
2005-11-10 |
2009-04-16 |
キュラジェン コーポレイション |
T細胞の免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
|
JP2009515552A
(ja)
*
|
2005-11-17 |
2009-04-16 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
α4β7インテグリン反応性ヒト化免疫グロブリン
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
KR101439828B1
(ko)
|
2005-11-30 |
2014-09-17 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
AU2006319358B2
(en)
|
2005-11-30 |
2012-01-19 |
AbbVie Deutschland GmbH & Co. KG |
Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
JP5312039B2
(ja)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄の関与する状態の処置
|
AU2006321593B2
(en)
|
2005-12-07 |
2012-10-04 |
E. R. Squibb & Sons, L.L.C. |
CTLA-4 antibody dosage escalation regimens
|
US20070134249A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Genitope Corporation |
Combination therapy and antibody panels
|
KR101158959B1
(ko)
|
2005-12-13 |
2012-07-09 |
일라이 릴리 앤드 캄파니 |
항-il-17 항체
|
AR056857A1
(es)
*
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
ES2521679T3
(es)
|
2006-01-18 |
2014-11-13 |
Merck Patent Gmbh |
Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
|
CN103215293B
(zh)
|
2006-01-27 |
2015-10-28 |
比奥根Ma公司 |
Nogo受体拮抗剂
|
EP1987361A4
(de)
*
|
2006-01-30 |
2009-03-04 |
Invitrogen Corp |
Zusammensetzungen und verfahren zur erkennung und quantifizierung toxischer substanzen in krankheitsstadien
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
EP2441469A1
(de)
|
2006-03-14 |
2012-04-18 |
Oregon Health and Science University |
Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis
|
EP4316465A3
(de)
|
2006-03-15 |
2024-04-24 |
Alexion Pharmaceuticals, Inc. |
Behandlung paroxysmaler nächtlicher hämoglobinurie-patienten mit einem komplementhemmer
|
CN103641915B
(zh)
|
2006-03-27 |
2017-04-12 |
医学免疫有限公司 |
Gm‑csf受体结合元件
|
SG170804A1
(en)
|
2006-03-30 |
2011-05-30 |
Meiji Seika Kaisha |
Pseudomonas aeruginosa outer membrane protein pa0427
|
RU2429014C2
(ru)
|
2006-03-31 |
2011-09-20 |
Массачусетс Инститьют Оф Текнолоджи |
Лечение опухолей, экспрессирующих мутантные рецепторы egf
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
EP2010226B1
(de)
|
2006-04-07 |
2014-01-15 |
The Research Foundation of State University of New York |
Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
EP2666478A3
(de)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Anwendungen und Zusammensetzungen zur Behandlung von Schuppenflechte
|
US9624295B2
(en)
|
2006-04-10 |
2017-04-18 |
Abbvie Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
US8784810B2
(en)
*
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
MX2008013363A
(es)
|
2006-04-20 |
2009-03-26 |
Jackson H M Found Military Med |
Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga.
|
US8202977B2
(en)
|
2006-04-21 |
2012-06-19 |
Minister for Primary Industries For And On Behalf Of The State Of New South Wales |
Pestivirus species
|
US20070254338A1
(en)
*
|
2006-04-24 |
2007-11-01 |
Amgen Inc. |
Method for making recombinant protein using complementation dependent DHFR mutants
|
US8022188B2
(en)
*
|
2006-04-24 |
2011-09-20 |
Abbott Laboratories |
Immunosuppressant binding antibodies and methods of obtaining and using same
|
JP2009535126A
(ja)
*
|
2006-04-27 |
2009-10-01 |
バーンズ−ジューイッシュ ホスピタル |
標的組織の検出とイメージング
|
US20090298093A1
(en)
*
|
2006-04-27 |
2009-12-03 |
Roberto Polakiewicz |
Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
|
AU2007249698A1
(en)
|
2006-05-15 |
2007-11-22 |
University Of Kentucky |
Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
|
EP2027284A2
(de)
*
|
2006-05-18 |
2009-02-25 |
Sanofi-Aventis |
Verwendung von adamts4-gen- und -protein-polymorphismen
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US8796429B2
(en)
*
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US7862812B2
(en)
*
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US20080138334A1
(en)
|
2006-05-31 |
2008-06-12 |
Sabbadini Roger A |
Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
GB0611116D0
(en)
|
2006-06-06 |
2006-07-19 |
Oxford Genome Sciences Uk Ltd |
Proteins
|
AT503690A1
(de)
|
2006-06-09 |
2007-12-15 |
Biomay Ag |
Hypoallergene moleküle
|
SG177907A1
(en)
|
2006-06-14 |
2012-02-28 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
JP5597793B2
(ja)
*
|
2006-06-19 |
2014-10-01 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ilt3結合分子およびその使用
|
LT2029173T
(lt)
|
2006-06-26 |
2016-11-10 |
Macrogenics, Inc. |
Fc riib specifiniai antikūnai ir jų panaudojimo būdai
|
EP2032989B2
(de)
|
2006-06-30 |
2015-10-28 |
Merck Sharp & Dohme Corp. |
Igfbp2-biomarker
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
TWI498137B
(zh)
*
|
2006-06-30 |
2015-09-01 |
Abbvie Biotechnology Ltd |
自動注射裝置
|
DK2041270T3
(da)
|
2006-07-13 |
2014-01-27 |
Wyeth Llc |
Fremstilling af glycoproteiner
|
CN101622276B
(zh)
*
|
2006-07-18 |
2015-04-22 |
赛诺菲-安万特 |
用于治疗癌症的抗epha2的拮抗抗体
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
CA2659820A1
(en)
|
2006-08-04 |
2008-02-14 |
Novartis Ag |
Ephb3-specific antibody and uses thereof
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
DK2383297T5
(da)
|
2006-08-14 |
2022-07-04 |
Xencor Inc |
Optimerede antistoffer rettet mod CD19
|
GEP20125612B
(en)
|
2006-08-18 |
2012-08-27 |
Novartis Ag |
Prlr-specific antibody and usage thereof
|
EP2064243A2
(de)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistische lichtspezifische menschliche monoklonale antikörper
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
GB0617429D0
(en)
|
2006-09-05 |
2006-10-18 |
Electrophoretics Ltd |
Markers of renal transplant rejection and renal damage
|
EP2061810B1
(de)
|
2006-09-05 |
2014-11-12 |
Alexion Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung antikörper-vermittelter nervenleiden
|
US20080064045A1
(en)
*
|
2006-09-07 |
2008-03-13 |
Huaiqin Wu |
Biomarker fragments for the detection of human BNP
|
ES2902063T3
(es)
|
2006-09-08 |
2022-03-24 |
Abbvie Bahamas Ltd |
Proteínas de unión a interleucina-13
|
EP2500416A1
(de)
|
2006-09-13 |
2012-09-19 |
Abbott Laboratories |
Verbesserungen an Zellkulturen
|
AU2007294731B2
(en)
|
2006-09-13 |
2014-04-17 |
Abbvie Inc. |
Cell culture improvements
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
EP2076287A2
(de)
*
|
2006-10-12 |
2009-07-08 |
Wyeth |
Verfahren und zusammensetzungen mit verringerter opaleszenz
|
JP2010506842A
(ja)
|
2006-10-16 |
2010-03-04 |
メディミューン,エルエルシー |
半減期が短縮された分子、その組成物および使用
|
WO2008060813A2
(en)
|
2006-10-19 |
2008-05-22 |
Merck & Co., Inc. |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
CA2915679C
(en)
|
2006-10-20 |
2017-12-12 |
Celera Corporation |
Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
|
JP5795833B2
(ja)
|
2006-10-27 |
2015-10-14 |
エルパス・インコーポレイテッドLpath, Inc. |
スフィンゴシン−1−リン酸と結合させるための組成物および方法
|
WO2008055072A2
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
MX2009004519A
(es)
|
2006-11-03 |
2009-05-12 |
Wyeth Corp |
Sustancias que inhiben la glucolisis en un cultivo de celulas.
|
WO2008063933A2
(en)
|
2006-11-10 |
2008-05-29 |
Massachusetts Institute Of Technology |
Pak modulators
|
EP2094282A4
(de)
*
|
2006-11-15 |
2010-05-05 |
Functional Genetics Inc |
Antikörper gegen tsg101 und verwendungen davon zur behandlung von virusinfektionen
|
WO2008064306A2
(en)
*
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
EP2431053A1
(de)
|
2006-11-27 |
2012-03-21 |
Patrys Limited |
Neues glykosyliertes Zielpeptid in neoplastischen Zellen
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
EP2687232A1
(de)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Verfahren zur Behandlung von systemischem Lupus erythematodes
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
EP2628752A1
(de)
|
2006-12-14 |
2013-08-21 |
Merck Sharp & Dohme Corp. |
Entwickelter Antikörper gegen TSLP
|
US7935791B2
(en)
|
2006-12-18 |
2011-05-03 |
Genentech, Inc. |
Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
DK2740744T3
(da)
|
2007-01-09 |
2018-04-23 |
Biogen Ma Inc |
Sp35-antistoffer og anvendelser deraf
|
NZ578065A
(en)
|
2007-01-16 |
2012-09-28 |
Abbott Lab |
Methods for treating psoriasis with an antibody which binds to an epitope
|
PT2842967T
(pt)
|
2007-01-18 |
2017-01-13 |
Lilly Co Eli |
Fab beta amilóide peguilado
|
MX2009007597A
(es)
|
2007-01-18 |
2009-07-22 |
Merck Patent Gmbh |
Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer.
|
ES2426158T3
(es)
|
2007-01-22 |
2013-10-21 |
Genentech, Inc. |
Precipitación con polielectrolito y purificación de anticuerpos
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
EP1958645A1
(de)
|
2007-02-13 |
2008-08-20 |
Biomay AG |
Peptide abgeleitet vom Hauptallergens von Traubenkraut (Ambrosia artemisiifolia) und deren Anwendung
|
US7883705B2
(en)
|
2007-02-14 |
2011-02-08 |
Kyowa Hakko Kirin Co., Ltd. |
Anti FGF23 antibody and a pharmaceutical composition comprising the same
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
DK2130044T3
(en)
|
2007-02-16 |
2017-02-06 |
Genzyme Corp |
PROCEDURE FOR IDENTIFYING THE RISK OF A THYRODOIDE DISORDER
|
US8685666B2
(en)
*
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
US8114606B2
(en)
*
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
EP2126105A4
(de)
*
|
2007-02-20 |
2010-11-03 |
Anaptysbio Inc |
Somatische hyperpermutationssysteme
|
US20100111966A1
(en)
*
|
2007-02-23 |
2010-05-06 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
CA2678749C
(en)
|
2007-02-23 |
2018-03-13 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
EP2121745A2
(de)
|
2007-02-26 |
2009-11-25 |
Oxford Genome Sciences (UK) Limited |
Proteine
|
WO2008104386A2
(en)
*
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
EP2395025A1
(de)
|
2007-02-28 |
2011-12-14 |
Schering Corporation |
Gentechnisch hergestellte anti-il-23r-antikörper
|
JP5596980B2
(ja)
|
2007-02-28 |
2014-10-01 |
アメリカ合衆国 |
ブラキュリポリペプチドおよび使用方法
|
KR20090127326A
(ko)
*
|
2007-03-02 |
2009-12-10 |
와이어쓰 |
폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
MX2009009782A
(es)
|
2007-03-15 |
2010-09-10 |
Ludwig Inst Cancer Res |
Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
|
NZ580245A
(en)
|
2007-03-22 |
2012-01-12 |
Biogen Idec Inc |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
EP1975184A3
(de)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serin- oder Threonin-Phosphorylationsorte
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
GB0706070D0
(en)
|
2007-03-28 |
2007-05-09 |
Scancell Ltd |
Nucleic acids
|
NZ598881A
(en)
*
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
CN103275220B
(zh)
|
2007-04-02 |
2016-01-20 |
菲洛根股份公司 |
与肿瘤转移的新生血管有关的纤连蛋白的ed-a抗原
|
EP1985295A1
(de)
|
2007-04-04 |
2008-10-29 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Selektive Inhibitoren der CB2-Rezeptorexpression und/oder Aktivität zur Behandlung von Adipositas und Krankheiten im Zusammenhang mit Adipositas
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
US8003097B2
(en)
*
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
RU2523894C2
(ru)
*
|
2007-04-18 |
2014-07-27 |
Янссен Альцгеймер Иммунотерапи |
Предупреждение и лечение церебральной амилоидной ангиопатии
|
EP1983002A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
US20100143336A1
(en)
|
2007-04-26 |
2010-06-10 |
Opsona Therapeutics Limited |
Toll-like receptor binding epitope and compositions for binding thereto
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2164868B1
(de)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
|
EP3456733A1
(de)
|
2007-05-11 |
2019-03-20 |
Genzyme Corporation |
Verfahren zur herstellung eines sekretierten proteins
|
EP2068927B1
(de)
|
2007-05-14 |
2015-10-21 |
MedImmune, LLC |
Verfahren zur reduzierung eosinophiler spiegel
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
ES2585702T3
(es)
|
2007-05-30 |
2016-10-07 |
Lpath, Inc |
Composiciones y métodos para la unión al ácido lisofosfatídico
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
CA2691075C
(en)
*
|
2007-06-15 |
2017-04-11 |
Daniela Gast |
Treatment of tumors using specific anti-l1 antibody
|
US20080317768A1
(en)
|
2007-06-21 |
2008-12-25 |
Boeing Company |
Bioconjugated nanoparticles
|
EP2175017A4
(de)
*
|
2007-06-29 |
2010-10-27 |
Meiji Seika Kaisha |
Protein pa4710 der äusseren membran von pseudomonas aeruginosa
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
EP2167541B1
(de)
|
2007-07-25 |
2012-12-19 |
Philogen S.p.A. |
Das fibronektin ed-a-antigen ist mit der neovaskulatur von tumormetastasen assoziiert
|
JP2010534719A
(ja)
*
|
2007-07-27 |
2010-11-11 |
ファイザー・リミテッド |
沈殿化による抗体精製方法
|
DK2182983T3
(da)
|
2007-07-27 |
2014-07-14 |
Janssen Alzheimer Immunotherap |
Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
|
EP2023144A1
(de)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
|
JP5659014B2
(ja)
|
2007-08-02 |
2015-01-28 |
ジリード バイオロジクス,インク. |
線維症、腫瘍浸潤、血管新生及び転移の治療及び診断のための方法及び組成物
|
EP2185578A2
(de)
|
2007-08-03 |
2010-05-19 |
Spirogene Pty Ltd |
Gene und proteine von brachyspira hyodysenteriae und anwendungen davon
|
US8734788B2
(en)
|
2007-08-03 |
2014-05-27 |
Opsona Therapeutics Ltd |
Composition and method for treatment of reperfusion injury and tissue damage
|
CA2696164C
(en)
|
2007-08-13 |
2018-06-12 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
WO2009023265A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
CA2698203C
(en)
|
2007-08-29 |
2018-09-11 |
Sanofi-Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their use
|
NZ599756A
(en)
*
|
2007-08-30 |
2013-09-27 |
Curedm Group Holdings Llc |
Compositions and methods of using proislet peptides and analogs thereof
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
AU2008298904B2
(en)
*
|
2007-09-14 |
2014-10-16 |
Amgen Inc. |
Homogeneous antibody populations
|
EP2573104A1
(de)
|
2007-09-24 |
2013-03-27 |
Cornell University |
Immunogene Proteine aus der genombasierten äußeren Membran von Leptospira sowie darauf basierende Zusammensetzungen und Verfahren
|
EP2195341B1
(de)
|
2007-09-26 |
2017-03-22 |
UCB Biopharma SPRL |
Fusionsantikörper mit dualer spezifität
|
GB0718843D0
(en)
|
2007-09-26 |
2007-11-07 |
Cancer Rec Tech Ltd |
Materials and methods relating to modifying the binding of antibodies
|
US8470560B2
(en)
|
2007-10-03 |
2013-06-25 |
The United States Of America As Represented By The Secretary Of The Army |
CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
|
JP5674469B2
(ja)
*
|
2007-10-11 |
2015-02-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
LINGO−1アンタゴニストおよびTrkBアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
JO3076B1
(ar)
*
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0720250D0
(en)
|
2007-10-17 |
2007-11-28 |
Univ Edinburgh |
Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
|
US8143224B2
(en)
|
2007-10-23 |
2012-03-27 |
The Cleveland Clinic Foundation |
Oxidant resistant apolipoprotein A-1 and mimetic peptides
|
US8361465B2
(en)
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
EP2209805B1
(de)
|
2007-10-30 |
2017-09-06 |
Philogen S.p.A. |
Mit rheumatoider arthritis assoziiertes antigen
|
AU2008324800B2
(en)
|
2007-11-05 |
2014-03-27 |
Astrazeneca Ab |
Methods of treating scleroderma
|
US8039212B2
(en)
|
2007-11-05 |
2011-10-18 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
|
CN101918540B
(zh)
*
|
2007-11-08 |
2016-05-11 |
比奥根Ma公司 |
Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
|
JP5580205B2
(ja)
|
2007-11-19 |
2014-08-27 |
セレラ コーポレーション |
肺癌マーカーとその使用
|
EP2062920A3
(de)
|
2007-11-21 |
2009-06-17 |
Peter Hornbeck |
Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
|
WO2015164330A1
(en)
|
2014-04-21 |
2015-10-29 |
Millennium Pharmaceuticals, Inc. |
Anti-psyk antibody molecules and use of same for syk-targeted therapy
|
WO2009079242A2
(en)
|
2007-12-05 |
2009-06-25 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
CN105001333B
(zh)
|
2007-12-14 |
2019-05-17 |
诺沃—诺迪斯克有限公司 |
抗人nkg2d抗体及其用途
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
RU2490278C2
(ru)
|
2007-12-21 |
2013-08-20 |
Медиммун Лимитед |
ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
|
AU2008342152B2
(en)
|
2007-12-25 |
2013-06-27 |
Meiji Seika Pharma Co., Ltd. |
Component protein PA1698 for type-III secretion system of Pseudomonas aeruginosa
|
SI2808343T1
(sl)
|
2007-12-26 |
2019-10-30 |
Xencor Inc |
Fc-variante s spremenjeno vezavo na FcRn
|
WO2009086411A2
(en)
*
|
2007-12-27 |
2009-07-09 |
Abbott Laboratories |
Negative mimic antibody for use as a blocking reagent in bnp immunoassays
|
WO2009083246A1
(en)
|
2007-12-31 |
2009-07-09 |
Bayer Schering Pharma Aktiengesellschaft |
Antibodies to tnf alpha
|
AU2009204467B2
(en)
|
2008-01-11 |
2012-09-06 |
Adheron Therapeutics, Inc. |
Cadherin-11 ECl domain antagonists for treating inflammatory joint disorders
|
CN101918555B
(zh)
|
2008-01-11 |
2013-11-06 |
株式会社遗传科技 |
人源化抗整联蛋白α9抗体及其应用
|
CA3108119C
(en)
|
2008-01-15 |
2024-01-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
WO2009092806A2
(en)
|
2008-01-25 |
2009-07-30 |
Aarhus Universitet |
Selective exosite inhibition of papp-a activity against igfbp-4
|
CN101952454B
(zh)
|
2008-02-08 |
2014-06-04 |
米迪缪尼有限公司 |
具有减弱的Fc配体亲和性的抗IFNAR1抗体
|
US20090221620A1
(en)
|
2008-02-20 |
2009-09-03 |
Celera Corporation |
Gentic polymorphisms associated with stroke, methods of detection and uses thereof
|
EP2363407A1
(de)
|
2008-02-28 |
2011-09-07 |
Murdoch University |
Neuartige Brachyspira-Sequenzen, immunogene Zusammensetzungen, Herstellungsverfahren dafür und Verwendung davon
|
US8962803B2
(en)
*
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
EP2098536A1
(de)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
|
NO2842575T3
(de)
|
2008-03-18 |
2018-02-24 |
|
|
NZ587765A
(en)
|
2008-03-18 |
2013-02-22 |
Abbott Lab |
Methods for treating psoriasis
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
EP2105742A1
(de)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Verwendung von Kathepsin-C
|
CN102046651B
(zh)
|
2008-03-27 |
2014-08-06 |
普利奥尼克斯股份公司 |
短螺旋体的新序列、免疫原性组合物、制备方法及其用途
|
DK2274008T3
(da)
|
2008-03-27 |
2014-05-12 |
Zymogenetics Inc |
Sammensætninger og fremgangsmåder til hæmning af PDGFRBETA og VEGF-A
|
EP2274437B1
(de)
|
2008-04-10 |
2015-12-23 |
Cell Signaling Technology, Inc. |
Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
|
AU2008201871A1
(en)
*
|
2008-04-16 |
2009-11-26 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Inhibition of angiogenesis and tumor metastasis
|
WO2009131256A1
(en)
|
2008-04-24 |
2009-10-29 |
Gene Techno Science Co., Ltd. |
Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
|
US20090269786A1
(en)
*
|
2008-04-25 |
2009-10-29 |
The Board Of Trustees Of The University Of Illinois |
RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
|
US20110229460A1
(en)
*
|
2008-05-01 |
2011-09-22 |
Gtc Biotherapeutics, Inc. |
anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
ES2458541T3
(es)
|
2008-05-02 |
2014-05-06 |
Seattle Genetics, Inc. |
Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
|
MY159667A
(en)
|
2008-05-09 |
2017-01-13 |
Abbvie Inc |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
CA2726131C
(en)
|
2008-05-29 |
2018-03-13 |
Baoming Jiang |
Expression and assembly of human group c rotavirus-like particles and uses thereof
|
EP2304439A4
(de)
|
2008-05-29 |
2012-07-04 |
Nuclea Biotechnologies Llc |
Anti-phospho-akt-antikörper
|
ES2595362T3
(es)
|
2008-06-16 |
2016-12-29 |
Patrys Limited |
Anticuerpos LM, fragmentos funcionales, antígeno diana LM-1 y métodos para prepararlos y usarlos
|
WO2009154770A2
(en)
|
2008-06-18 |
2009-12-23 |
The Texas A & M University System |
Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
|
EP2307042B1
(de)
|
2008-06-25 |
2014-03-26 |
H. Lundbeck A/S |
Modulierung des trpv : vps10p domänen-rezeptorsystems zur behandlung von schmerzen
|
FR2933702A1
(fr)
*
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
TW201014602A
(en)
|
2008-07-08 |
2010-04-16 |
Abbott Lab |
Prostaglandin E2 binding proteins and uses thereof
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
EP2310525B1
(de)
|
2008-07-09 |
2014-02-26 |
Celera Corporation |
Mit herz-kreislauf-erkrankungen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
US20100173828A1
(en)
*
|
2008-07-25 |
2010-07-08 |
Abbott Gmbh & Co. Kg |
Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
|
CA2735433C
(en)
|
2008-09-07 |
2016-02-16 |
Glyconex Inc. |
Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
|
US20100061995A1
(en)
*
|
2008-09-08 |
2010-03-11 |
Damian Michael Carragher |
Immunotherapy To Treat Or Prevent Viral Infection
|
US20110236376A1
(en)
*
|
2008-09-08 |
2011-09-29 |
Smiley Stephen T |
Non-neutralizing immunity to influenza to prevent secondary bacterial pneumonia
|
EP2927244A1
(de)
|
2008-09-19 |
2015-10-07 |
MedImmune, LLC |
Gegen DLL4 gerichtete Antikörper und ihre Verwendung
|
US8658350B2
(en)
|
2008-09-22 |
2014-02-25 |
Oregon Health & Science University |
Methods for detecting Mycobacterium tuberculosis disease
|
CA2739357A1
(en)
|
2008-09-23 |
2010-04-08 |
Wyeth Llc |
Methods for predicting production of activating signals by cross-linked binding proteins
|
EP2334300B1
(de)
|
2008-09-24 |
2016-02-17 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Zusammensetzung und verfahren zur behandlung von vorzeitigen wehen
|
GB0817891D0
(en)
|
2008-09-30 |
2008-11-05 |
Medical Res Council |
Antibodies against il-25
|
JP2012504650A
(ja)
|
2008-10-02 |
2012-02-23 |
セルタクシス,インコーポレイテッド |
免疫細胞の負の走化性の調節方法
|
CA2932207A1
(en)
|
2008-10-20 |
2010-12-09 |
Abbvie Inc. |
Isolation and purification of antibodies using protein a affinity chromatography
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
EP2350270B1
(de)
|
2008-10-24 |
2018-03-07 |
The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services |
Menschliche ebolavirus-spezies sowie zusammensetzungen und verfahren dafür
|
DK3199553T3
(da)
|
2008-10-29 |
2019-07-22 |
Circular Commitment Company |
Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
|
KR101581986B1
(ko)
|
2008-10-29 |
2016-01-04 |
아블린쓰 엔.브이. |
단일 도메인 항원 결합 분자의 제형
|
CA2739352C
(en)
|
2008-10-29 |
2021-07-13 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
EP2356251A1
(de)
|
2008-11-07 |
2011-08-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin und krebs
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
WO2010062896A1
(en)
*
|
2008-11-28 |
2010-06-03 |
Abbott Laboratories |
Stable antibody compositions and methods for stabilizing same
|
EP2374001A4
(de)
*
|
2008-12-05 |
2013-03-13 |
Lpath Inc |
Antikörperdesign unter verwendung von anti-lipid-antikörper-kristallstrukturen
|
US8401799B2
(en)
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
SI2786762T1
(sl)
|
2008-12-19 |
2019-07-31 |
Macrogenics, Inc. |
Kovalentna diatelesa in njihove uporabe
|
GB0823309D0
(en)
|
2008-12-19 |
2009-01-28 |
Univ Bath |
Functionalising reagents and their uses
|
EP2373343B1
(de)
|
2008-12-19 |
2015-02-11 |
Philogen S.p.A. |
Immuncytokine für tumor-therapie mit chemotherapeutika
|
US20100159485A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Centre For Dna Fingerprinting And Diagnostics |
Detection of mycobacterium tuberculosis
|
CN102439041B
(zh)
|
2008-12-19 |
2016-05-04 |
H.隆德贝克有限公司 |
用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
|
EP2379595A2
(de)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Gegen a5b1 gerichtete gezielt bindende mittel und anwendungen davon
|
EP2201982A1
(de)
|
2008-12-24 |
2010-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Histamin-H4-Rezeptorantagonisten zur Behandlung von Vestibularisstörungen
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
EP2373339B1
(de)
|
2009-01-06 |
2017-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Ein b-zelldepletionswirkstoff zur behandlung von atherosklerose
|
US20110318302A1
(en)
|
2009-01-07 |
2011-12-29 |
Kathrin Schwager |
Cancer Treatment
|
EP2379116B1
(de)
|
2009-01-07 |
2015-08-26 |
Philogen S.p.A. |
Mit endometriose assoziierte antigene
|
BRPI1007345A2
(pt)
|
2009-01-20 |
2019-04-16 |
H. ZADEH Homayoun |
regeneração óssea de anticorpo mediado
|
CA2750581A1
(en)
|
2009-01-21 |
2010-07-29 |
Oxford Biotherapeutics Ltd. |
Pta089 protein
|
WO2010085590A1
(en)
|
2009-01-23 |
2010-07-29 |
Biosynexus Incorporated |
Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
|
EP2389587B1
(de)
|
2009-01-26 |
2013-12-25 |
Electrophoretics Limited |
Diagnostisches und prognostisches verfahren in verbindung mit morbus alzheimer
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
KR20110110349A
(ko)
*
|
2009-01-29 |
2011-10-06 |
아보트 러보러터리즈 |
Il-1 결합 단백질
|
EP2219029A1
(de)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US9085795B2
(en)
*
|
2009-02-04 |
2015-07-21 |
Molecular Innovations, Inc. |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
|
US9079942B2
(en)
*
|
2009-02-09 |
2015-07-14 |
Epitomics, Inc. |
CDR-anchored amplification method
|
US20120165340A1
(en)
|
2009-02-11 |
2012-06-28 |
Ludwing Institute For Cancer Research Ltd. |
Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
|
EP2396035A4
(de)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
|
HUE033661T2
(en)
|
2009-02-16 |
2017-12-28 |
Cerenis Therapeutics Holding Sa |
Apolipoprotein A-1 mimetics
|
WO2010096658A1
(en)
|
2009-02-19 |
2010-08-26 |
The Cleveland Clinic Foundation |
Corin as a marker for heart failure
|
US8030026B2
(en)
*
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
EP2403530B1
(de)
|
2009-02-27 |
2016-05-11 |
Massachusetts Institute of Technology |
Manipulierte proteine mit hoher affinität für dota-chelate
|
WO2010099472A2
(en)
|
2009-02-27 |
2010-09-02 |
The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services |
Spanx-b polypeptides and their use
|
EP2810652A3
(de)
|
2009-03-05 |
2015-03-11 |
AbbVie Inc. |
IL-17-bindende Proteine
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
KR101667227B1
(ko)
|
2009-03-10 |
2016-10-18 |
가부시키가이샤 진 테크노 사이언스 |
인간화된 k33n 단일 클론 항체의 제조, 발현 및 해석
|
WO2010106542A2
(en)
|
2009-03-19 |
2010-09-23 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
USE OF NKp46 FOR PREVENTING DIABETES
|
WO2010106187A2
(en)
|
2009-03-20 |
2010-09-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders
|
EP2411412B1
(de)
|
2009-03-24 |
2015-05-27 |
Teva Biopharmaceuticals USA, Inc. |
Humanisierte antikörper gegen licht und anwendungen davon
|
WO2010112033A2
(en)
|
2009-03-31 |
2010-10-07 |
Østjysk Innovation A/S |
Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
GB0905972D0
(en)
|
2009-04-06 |
2009-05-20 |
Medical Res Council |
Antibodies against IL-17BR
|
US20120121706A1
(en)
|
2009-04-10 |
2012-05-17 |
Tufts Medical Center, Inc. |
PAR-1 Activation by Metalloproteinase-1 (MMP-1)
|
EP2417984B1
(de)
|
2009-04-10 |
2016-03-30 |
Kyowa Hakko Kirin Co., Ltd. |
Verfahren zur behandlung von blutkrebs mittels anti-tim-antikörper
|
AR075989A1
(es)
|
2009-04-10 |
2011-05-11 |
Lilly Co Eli |
Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
US8722860B2
(en)
|
2009-04-16 |
2014-05-13 |
Abbvie Biotherapeutics Inc. |
Anti-TNF-α antibodies and their uses
|
EP2419446A4
(de)
*
|
2009-04-17 |
2013-01-23 |
Lpath Inc |
Humanisierte antikörperzusammensetzungen und verfahren zur bindung von lysophosphatidsäure
|
AU2010236257A1
(en)
*
|
2009-04-17 |
2011-11-03 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
EP2419121B1
(de)
|
2009-04-17 |
2018-07-18 |
New York University |
Auf rezeptoren der tnf-familie gerichtete peptide als antagonisten der tnf-wirkung, ihre zusammensetzungen, verfahren und verwendung
|
WO2010125566A2
(en)
|
2009-04-27 |
2010-11-04 |
Technion Research And Development Foundation Ltd. |
Markers for cancer detection
|
WO2010126066A1
(ja)
|
2009-04-27 |
2010-11-04 |
協和発酵キリン株式会社 |
血液腫瘍治療を目的とした抗IL-3Rα抗体
|
JP5677411B2
(ja)
|
2009-04-29 |
2015-02-25 |
アッヴィ バイオテクノロジー リミテッド |
自動注入機器
|
EP2424891B1
(de)
|
2009-04-29 |
2014-06-11 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Monoklonale erg-antikörper
|
WO2010128016A2
(en)
|
2009-05-04 |
2010-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Par2 agonists for use in the treatment or prevention of influenza virus type a infections
|
EP2429582A4
(de)
|
2009-05-13 |
2013-01-23 |
Genzyme Corp |
Anti-human-cd52-immunglobuline
|
GB0908425D0
(en)
|
2009-05-15 |
2009-06-24 |
Medical Res Council |
Medical use
|
CA2682429A1
(en)
*
|
2009-05-20 |
2010-11-20 |
Gary Levy |
An assay for measuring plasma fgl-2 and methods and uses thereof
|
HUE037300T2
(hu)
|
2009-05-20 |
2018-08-28 |
Inst Nat Sante Rech Med |
Szerotonin 5-HT3 receptor antagonisták lezionális vesztibuláris zavarok kezelésében való felhasználásra
|
EP2253316B1
(de)
|
2009-05-20 |
2013-08-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Serotonin-5-HT3-Rezeptorantagonisten zur Verwendung bei der Behandlung oder Prävention einer Innenohr-Pathologie mit Vestibularisdefiziten
|
EA201101651A1
(ru)
|
2009-05-25 |
2012-08-30 |
Мерк Патент Гмбх |
Непрерывное введение интегриновых лигандов для лечения рака
|
US20100317539A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Guo-Liang Yu |
Library of Engineered-Antibody Producing Cells
|
MX346002B
(es)
|
2009-06-17 |
2017-03-01 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-vegf y sus usos.
|
ES2677564T3
(es)
|
2009-06-19 |
2018-08-03 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Método y composición farmacéutica para su uso en el tratamiento de trastornos neurodegenerativos
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
WO2011005581A2
(en)
|
2009-06-24 |
2011-01-13 |
Lpath, Inc. |
Methods of increasing neuronal differntiation using antibodies to lysophoshatidic acid
|
US8268550B2
(en)
*
|
2009-06-26 |
2012-09-18 |
Massachusetts Institute Of Technology |
Compositions and methods for identification of PARP function, inhibitors, and activators
|
US20110097329A1
(en)
|
2009-06-26 |
2011-04-28 |
Massachusetts Institute Of Technology |
Compositions and methods for treating cancer and modulating stress granule formation
|
US8435961B2
(en)
*
|
2009-06-26 |
2013-05-07 |
Massachusetts Institute Of Technology |
Methods and compositions for increasing the activity of inhibitory RNA
|
WO2011001276A1
(en)
|
2009-06-30 |
2011-01-06 |
Philogen S.P.A. |
Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
|
EP2448966B1
(de)
|
2009-07-03 |
2018-11-14 |
Avipep Pty Ltd |
Immunkonjugate und verfahren zu ihrer herstellung
|
CA2766861A1
(en)
|
2009-07-09 |
2011-01-13 |
F. Hoffmann-La Roche Ag |
In vivo tumor vasculature imaging
|
WO2011008959A1
(en)
|
2009-07-15 |
2011-01-20 |
Abbott Laboratories |
Enhancement of cellular production through mechanotransduction
|
US9603954B2
(en)
|
2009-07-22 |
2017-03-28 |
Actinium Pharmaceuticals Inc. |
Methods for generating radioimmunoconjugates
|
EP2456428A1
(de)
|
2009-07-23 |
2012-05-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Selektive cb2-rezeptoragonisten zur prävention oder behandlung von alkoholbedingten lebererkrankungen
|
US8679488B2
(en)
|
2009-08-05 |
2014-03-25 |
Philogen S.P.A. |
Targeting of bone marrow neovasculature
|
US8568719B2
(en)
|
2009-08-13 |
2013-10-29 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (RSV) and methods of use
|
WO2011020024A2
(en)
|
2009-08-13 |
2011-02-17 |
The Johns Hopkins University |
Methods of modulating immune function
|
GB0914446D0
(en)
|
2009-08-18 |
2009-09-30 |
King S College London |
Bioconjugates and their uses in imaging
|
EP2467159A1
(de)
|
2009-08-20 |
2012-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Vla-4 als biomarker zur prognose und target zur behandlung der duchenne-muskeldystrophie
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
CN102002104A
(zh)
|
2009-08-28 |
2011-04-06 |
江苏先声药物研究有限公司 |
一种抗vegf的单克隆抗体及含有该抗体的药物组合物
|
EP3029070A1
(de)
|
2009-08-29 |
2016-06-08 |
AbbVie Inc. |
Therapeutische dll4-bindende proteine
|
EP2293072A1
(de)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Verwendung von Kathepsin H
|
WO2011023824A2
(en)
|
2009-08-31 |
2011-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Estrogen receptor modulators for the treatment of diseases involving plasmacytoid dendritic cells
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
US8293483B2
(en)
|
2009-09-11 |
2012-10-23 |
Epitomics, Inc. |
Method for identifying lineage-related antibodies
|
KR20140048229A
(ko)
*
|
2009-09-14 |
2014-04-23 |
애브비 인코포레이티드 |
건선을 치료하는 방법
|
US20110070227A1
(en)
|
2009-09-18 |
2011-03-24 |
Anna-Marie Novotney-Barry |
Treatment of Autoimmune and Inflammatory Diseases
|
EP2480573A1
(de)
|
2009-09-22 |
2012-08-01 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs durch modulation von mex-3
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
CA2776037A1
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd |
Anti-fibroblast activation protein antibodies and methods and uses thereof
|
WO2011040973A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
BR112012008665A2
(pt)
|
2009-10-12 |
2016-11-22 |
Pfizer |
tratamento de câncer
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
PT2488551T
(pt)
|
2009-10-16 |
2018-10-31 |
Inst Nat Sante Rech Med |
Anticorpos monoclonais contra a progastrina e suas utilizações
|
US9181306B2
(en)
|
2009-10-16 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
EP2490696A1
(de)
|
2009-10-20 |
2012-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von glukosehomöostase
|
RS60577B1
(sr)
|
2009-10-20 |
2020-08-31 |
Abbvie Inc |
Izolacija i prečišćavanje anti-il-13 antitela upotrebom protein a afinitetne hromatografije
|
IN2012DN02604A
(de)
|
2009-10-23 |
2015-09-04 |
Millennium Pharm Inc |
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
CN102781963B
(zh)
|
2009-10-27 |
2018-02-16 |
Ucb医药有限公司 |
功能修饰性NAv1.7抗体
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
TW201122101A
(en)
|
2009-10-28 |
2011-07-01 |
Facet Biotech Corp |
Anti-EGFR antibodies and their uses
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
WO2011054007A1
(en)
|
2009-11-02 |
2011-05-05 |
Oxford Biotherapeutics Ltd. |
Ror1 as therapeutic and diagnostic target
|
CN102782149B
(zh)
|
2009-11-04 |
2014-11-12 |
默沙东公司 |
经工程改造的抗-tslp抗体
|
WO2011054359A2
(en)
|
2009-11-06 |
2011-05-12 |
University Of Copenhagen |
Method for early detection of cancer
|
HUE035605T2
(en)
|
2009-11-13 |
2018-05-28 |
Daiichi Sankyo Europe Gmbh |
Materials and Methods for the Treatment or Prevention of HER-3-Related Diseases
|
EP2501397B1
(de)
|
2009-11-20 |
2017-10-04 |
Oregon Health and Science University |
Verfahren zum hervorrufen einer immunantwort auf tuberkulose
|
WO2011061340A1
(en)
|
2009-11-23 |
2011-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
WO2011064395A2
(en)
|
2009-11-30 |
2011-06-03 |
Inserm |
Inhibitors and antagonists of calcium channels in the treatment of asthma
|
WO2011068870A2
(en)
|
2009-12-01 |
2011-06-09 |
President And Fellows Of Harvard College |
Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
|
SG181563A1
(en)
*
|
2009-12-08 |
2012-07-30 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
EP2510012B1
(de)
|
2009-12-09 |
2017-04-19 |
Bayer Pharma Aktiengesellschaft |
Antikörper gegen c4.4a und deren verwendung
|
US20120283190A1
(en)
|
2009-12-09 |
2012-11-08 |
Institut National de la Santé et de la Recherche Medicale (INSERM) |
Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
|
RU2582401C2
(ru)
*
|
2009-12-15 |
2016-04-27 |
Эббви Байотекнолоджи Лтд |
Усовершенствованная пусковая кнопка для автоматического инъекционного устройства
|
EP2513148B1
(de)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2-antikörper und ihre verwendung
|
EA201270662A1
(ru)
|
2009-12-23 |
2013-01-30 |
4-Антибоди Аг |
Связывающие элементы для человеческого цитамегаловируса
|
CA2784610C
(en)
|
2009-12-23 |
2020-07-14 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
WO2011084882A2
(en)
|
2010-01-05 |
2011-07-14 |
Contrafect Corporation |
Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
|
EP2521782B1
(de)
|
2010-01-05 |
2019-04-10 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
FLT3-Rezeptorantagonisten zur Behandlung oder Vorbeugung von Schmerzstörungen
|
US20110177614A1
(en)
*
|
2010-01-15 |
2011-07-21 |
The Regents Of The University Of California |
Compositions and methods for detecting cancer
|
PT2523661T
(pt)
|
2010-01-15 |
2017-06-21 |
Inserm (Institut Nat De La Santé Et De La Rech Médicale) |
Inibidores de nkcc para o tratamento de autismo
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
WO2011091181A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
WO2011091177A1
(en)
|
2010-01-20 |
2011-07-28 |
Tolerx, Inc. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
US20120014956A1
(en)
|
2010-02-02 |
2012-01-19 |
Hartmut Kupper |
Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
|
EP2536432B1
(de)
|
2010-02-19 |
2018-08-08 |
Cornell University |
Verfahren zur behandlung demyelinisierender autoimmunerkrankungen und anderer autoimmun- oder entzündungserkrankungen
|
AU2011219029B2
(en)
|
2010-02-26 |
2017-02-02 |
Columbia University |
Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
EP2542582A4
(de)
|
2010-03-02 |
2013-12-04 |
Abbvie Inc |
Therapeutische dll4-bindende proteine
|
MX341536B
(es)
|
2010-03-03 |
2016-08-24 |
The Univ Of British Columbia * |
Epitopo y anticuerpos beta amiloide de oligomero especifico.
|
EP2542578A1
(de)
|
2010-03-05 |
2013-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Smoc1, tenascin-c und hirnkrebs
|
US8642557B2
(en)
|
2010-03-12 |
2014-02-04 |
Abbvie Biotherapeutics Inc. |
CTLA4 proteins and their uses
|
WO2011113904A1
(en)
|
2010-03-17 |
2011-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
|
WO2011113118A1
(en)
|
2010-03-19 |
2011-09-22 |
Katholieke Universiteit Leuven |
Drug tolerance/persistence of fungal biofilms
|
ES2717883T3
(es)
|
2010-03-25 |
2019-06-26 |
Ucb Biopharma Sprl |
Moléculas de DVD-LG estabilizadas con disulfuro
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
EP3222632A1
(de)
|
2010-03-26 |
2017-09-27 |
Memorial Sloan-Kettering Cancer Center |
Antikörper gegen muc16 und verfahren zur verwendung davon
|
EP2374816B1
(de)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon
|
US9441032B2
(en)
|
2010-04-07 |
2016-09-13 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
WO2011127412A2
(en)
|
2010-04-09 |
2011-10-13 |
Critical Care Diagnostics, Inc. |
Soluble human st-2 antibodies and assays
|
CA2796339C
(en)
|
2010-04-15 |
2020-03-31 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
SG10201502967RA
(en)
|
2010-04-16 |
2015-05-28 |
Biogen Ma Inc |
Anti-vla-4 antibodies
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
GB201006768D0
(en)
|
2010-04-22 |
2010-06-09 |
Cancer Rec Tech Ltd |
Method for obtaining dendritic cells
|
AU2011246893A1
(en)
|
2010-04-29 |
2012-11-08 |
Hadasit Medical Research Service And Development Co. Ltd. |
Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy
|
EP2563394B1
(de)
|
2010-04-30 |
2018-03-21 |
Beth Israel Deaconess Medical Center |
Verfahren und zusammensetzungen zur behandlung von zöliakie
|
ES2566934T3
(es)
|
2010-05-10 |
2016-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
|
SI2571532T1
(sl)
|
2010-05-14 |
2017-10-30 |
Abbvie Inc. |
Proteini, ki vežejo IL-1
|
GB201008541D0
(en)
|
2010-05-21 |
2010-07-07 |
Univ Geneve |
Diagnostic methods
|
WO2011145085A2
(en)
|
2010-05-21 |
2011-11-24 |
Procognia (Israel) Ltd |
Novel antibodies and methods of use for the treatment and diagnosis of cancer
|
US8853158B2
(en)
|
2010-05-25 |
2014-10-07 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor
|
JP2013534515A
(ja)
|
2010-06-01 |
2013-09-05 |
モナシュ ユニバーシティ |
プロセシングされていない受容体型チロシンキナーゼc−METに対する抗体
|
EP2579861A2
(de)
|
2010-06-02 |
2013-04-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Transglutaminase-2-inhibitoren zur verwendung bei der vorbeugung und behandlung einer schnell fortschreitenden glomerulonephritis
|
US8747854B2
(en)
|
2010-06-03 |
2014-06-10 |
Abbvie Biotechnology Ltd. |
Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
|
GB201009455D0
(en)
|
2010-06-04 |
2010-07-21 |
King S College London |
Nanoparticles and their uses in molecular imaging
|
BR112012031107A2
(pt)
|
2010-06-09 |
2017-07-25 |
Queen Mary & Westfield College |
molécula de ligação específica cultivada contra a proteína anx-a1 humana, linha de células de hibridoma, composição farmacêutica , uso da molécula de ligação específica e método para o tratamento de uma doença mediada por linfócitos t em um indivíduo com necessidade do mesmo
|
AR081434A1
(es)
|
2010-06-10 |
2012-08-29 |
Lilly Co Eli |
Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
AU2011268310A1
(en)
|
2010-06-16 |
2013-01-10 |
Abbvie Inc. |
Comparison of protein samples
|
EP2582365B1
(de)
|
2010-06-16 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Zusammensetzungen zur stimulierung der reepithelialisation während der wundheilung
|
AU2011268780A1
(en)
|
2010-06-25 |
2013-02-07 |
Aston University |
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
|
US20130150286A1
(en)
|
2010-06-25 |
2013-06-13 |
Jean-Claude Sirard |
Methods and pharmaceutical compositions for the treatment of respiratory tract infections
|
US9095591B2
(en)
|
2010-06-28 |
2015-08-04 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Pharmaceutical composition for use in the treatment of glaucoma
|
WO2012004565A1
(en)
|
2010-07-06 |
2012-01-12 |
Robert White |
Cancer biomarker brf1
|
US9485812B2
(en)
|
2010-07-08 |
2016-11-01 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
EA027835B1
(ru)
|
2010-07-09 |
2017-09-29 |
Круселл Холланд Б.В. |
Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
|
MX2013000301A
(es)
|
2010-07-09 |
2013-05-09 |
Biogen Idec Hemophilia Inc |
Factores quimericos de coagulacion.
|
LT2593128T
(lt)
|
2010-07-15 |
2018-06-25 |
Adheron Therapeutics, Inc. |
Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai
|
WO2012007880A2
(en)
|
2010-07-16 |
2012-01-19 |
Ablynx Nv |
Modified single domain antigen binding molecules and uses thereof
|
KR20130092561A
(ko)
|
2010-07-16 |
2013-08-20 |
메르크 파텐트 게엠베하 |
유방암 및/또는 뼈 전이의 치료에 사용하기 위한 펩티드
|
JP5972871B2
(ja)
|
2010-07-20 |
2016-08-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗il−23ヘテロ二量体特異的抗体
|
WO2012010696A1
(en)
|
2010-07-23 |
2012-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for cancer management targeting co-029
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
JP2013540694A
(ja)
|
2010-08-06 |
2013-11-07 |
ウー3・フアルマ・ゲー・エム・ベー・ハー |
Her3結合剤の前立腺治療における使用
|
US20130156791A1
(en)
|
2010-08-09 |
2013-06-20 |
Jean-luc Perfettini |
Methods and pharmaceutical compositions for the treatment of hiv-1 infections
|
CN103068848B
(zh)
|
2010-08-12 |
2015-11-25 |
伊莱利利公司 |
抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
EP3533803B1
(de)
|
2010-08-14 |
2021-10-27 |
AbbVie Inc. |
Anti-amyloid-beta antikörper
|
HUE058226T2
(hu)
|
2010-08-19 |
2022-07-28 |
Zoetis Belgium S A |
NGF elleni antitestek és alkalmazásuk
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
WO2012023085A1
(en)
|
2010-08-20 |
2012-02-23 |
Wyeth Llc |
Cell culture of growth factor-free adapted cells
|
NZ629913A
(en)
|
2010-08-23 |
2016-01-29 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
ES2715177T3
(es)
|
2010-09-01 |
2019-06-03 |
Genzyme Corp |
Tratamiento de infarto de miocardio usando antagonistas de tgf-beta
|
EP2611463A2
(de)
|
2010-09-03 |
2013-07-10 |
Stem Centrx, Inc. |
Identifzierung und anreicherung von zellsubpopulationen
|
WO2013119964A2
(en)
|
2012-02-08 |
2013-08-15 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
US20120122076A1
(en)
|
2010-09-20 |
2012-05-17 |
Abbott Laboratories |
Purification of antibodies using simulated moving bed chromatography
|
US20130195863A1
(en)
|
2010-09-28 |
2013-08-01 |
Philippe Clezardin |
Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
|
US9675693B2
(en)
|
2010-09-30 |
2017-06-13 |
Riken |
Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
ES2606140T3
(es)
|
2010-10-01 |
2017-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
JP6000959B2
(ja)
|
2010-10-19 |
2016-10-05 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
ヒト抗体ならびに神経疾患の処置のためのその診断的および治療的使用
|
JP6121906B2
(ja)
|
2010-10-22 |
2017-04-26 |
シアトル ジェネティクス,インコーポレーテッド |
アウリスタチン系抗体薬物複合体とPI3K−AKTmTOR経路インヒビターの間の相乗効果
|
SG10202100921YA
(en)
|
2010-10-27 |
2021-03-30 |
Univ New York State Res Found |
Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
|
US20120108651A1
(en)
|
2010-11-02 |
2012-05-03 |
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) |
Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
|
US20130224116A1
(en)
|
2010-11-05 |
2013-08-29 |
TransBio Ltd. |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
WO2012064286A1
(en)
|
2010-11-11 |
2012-05-18 |
Agency For Science, Technology And Research |
Targeting metabolic enzymes in human cancer
|
GB201019118D0
(en)
|
2010-11-11 |
2010-12-29 |
King S College |
Conjugates and their uses in molecular imaging
|
WO2012065055A2
(en)
|
2010-11-12 |
2012-05-18 |
The Rockefeller University |
Fusion proteins for hiv therapy
|
WO2012065937A1
(en)
|
2010-11-15 |
2012-05-24 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Anti-fungal agents
|
US9072766B2
(en)
|
2010-11-18 |
2015-07-07 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
|
CN103874707B
(zh)
|
2010-11-19 |
2017-04-19 |
卫材R&D管理有限公司 |
中和抗‑ccl20抗体
|
US20130336979A1
(en)
|
2010-12-01 |
2013-12-19 |
Fatima Smih |
Diagnostic and treatment of chronic heart failure
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
CN103534392A
(zh)
|
2010-12-01 |
2014-01-22 |
默沙东公司 |
表面锚定的fc-诱饵抗体展示系统
|
US9533041B2
(en)
|
2010-12-03 |
2017-01-03 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of heart failure
|
UY33807A
(es)
|
2010-12-17 |
2012-07-31 |
Sanofi Sa |
miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
KR20140003467A
(ko)
|
2010-12-20 |
2014-01-09 |
메디뮨 리미티드 |
항il-18 항체 및 그의 용도
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
EP2655607A4
(de)
|
2010-12-21 |
2014-05-14 |
Univ North Carolina |
Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
|
JP6147670B2
(ja)
|
2010-12-22 |
2017-06-14 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
改善された半減期を有する修飾された抗体
|
EP2659910B1
(de)
|
2010-12-27 |
2016-11-09 |
National University Corporation Nagoya University |
Screeningverfahren zur Identifizierung von Verbindungen die die durch Rezeptortyrosinkinase vermittelte Prosurvival-Signalisierung in Krebszellen hemmen
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
CA2824885A1
(en)
|
2011-01-19 |
2012-07-26 |
Bayer Intellectual Property Gmbh |
Binding proteins to inhibitors of coagulation factors
|
MX337208B
(es)
|
2011-01-24 |
2016-02-17 |
Abbvie Biotechnology Ltd |
Dispositivos de inyeccion automaticos que tienen superficies de agarre sobremoldeadas.
|
EP2668210B1
(de)
|
2011-01-26 |
2020-06-17 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und ihre verwendungen
|
US9669092B2
(en)
|
2011-02-02 |
2017-06-06 |
Emory University |
Antagonism of the VIP signaling pathway
|
WO2012106669A2
(en)
|
2011-02-04 |
2012-08-09 |
John Wayne Cancer Institute |
Foxc1 antibodies and methods of their use
|
WO2012110824A1
(en)
|
2011-02-18 |
2012-08-23 |
Astrazeneca Ab |
Binding agents with specificity for a nucleic acid modification
|
CN103501859B
(zh)
|
2011-03-02 |
2017-08-25 |
博格有限责任公司 |
基于细胞的探询式分析及其应用
|
EP2683736B1
(de)
|
2011-03-09 |
2018-01-17 |
Cell Signaling Technology, Inc. |
Verfahren und reagenzien zur erzeugung monoklonaler antikörper
|
WO2012125735A1
(en)
|
2011-03-15 |
2012-09-20 |
Abott Laboratories |
An integrated approach to the isolation and purification of antibodies
|
EP3235508B1
(de)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Zubereitungen enthaltend ein antikörperähnliches protein mit dualer v-region
|
TW201239355A
(en)
|
2011-03-23 |
2012-10-01 |
Abbott Lab |
Methods and systems for the analysis of protein samples
|
CN103547592A
(zh)
|
2011-03-30 |
2014-01-29 |
埃博灵克斯股份有限公司 |
使用针对TNFα的单结构域抗体治疗免疫病症的方法
|
EP2699598B1
(de)
|
2011-04-19 |
2019-03-06 |
Pfizer Inc |
Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
|
LT2699264T
(lt)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
|
WO2012143499A2
(de)
|
2011-04-21 |
2012-10-26 |
Bayer Intellectual Property Gmbh |
Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
|
WO2012142662A1
(en)
|
2011-04-21 |
2012-10-26 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
CN108578685A
(zh)
|
2011-04-21 |
2018-09-28 |
洛克菲勒大学 |
用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素
|
EP2518157A1
(de)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
MX367097B
(es)
|
2011-05-02 |
2019-08-05 |
Millennium Pharm Inc |
FORMULACION PARA ANTICUERPO ANTI-A4ß7.
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
GB201107467D0
(en)
|
2011-05-05 |
2011-06-15 |
Univ Leuven Kath |
Novel treatment of pain
|
US20140086827A1
(en)
|
2011-05-09 |
2014-03-27 |
The Cleveland Clinic Foundation |
Serum S100B And Uses Thereof
|
US9598496B2
(en)
|
2011-05-09 |
2017-03-21 |
Perseus Proteomics Inc. |
Antibody capable of specifically recognizing transferrin receptor
|
EP2524699A1
(de)
|
2011-05-17 |
2012-11-21 |
Trion Research GmbH |
Impfstoffzubereitung mit trifunktionalen Antikörpern mit Antigenimmunogenität verbessernden Eigenschaften
|
WO2012156430A1
(en)
|
2011-05-17 |
2012-11-22 |
Trion Research Gmbh |
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
KR102030531B1
(ko)
|
2011-05-21 |
2019-10-10 |
마크로제닉스, 인크. |
탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
US9410955B2
(en)
|
2011-06-01 |
2016-08-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method for predicting the risk of developing a colonic neoplasia
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170929A2
(en)
*
|
2011-06-08 |
2012-12-13 |
Indiana University Research And Technology Corporation |
Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
|
WO2012170969A2
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
GB201109965D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating estrogen receptor alpher(ER) positive cancer
|
HUE038509T2
(hu)
|
2011-06-10 |
2018-10-29 |
Medimmune Ltd |
Pseudomonas PSL elleni kötõmolekula és alkalmazása
|
GB201109966D0
(en)
|
2011-06-10 |
2011-07-27 |
Cancer Res Inst Royal |
Materials and methods for treating pten mutated or deficient cancer
|
CA2838973A1
(en)
|
2011-06-17 |
2012-12-20 |
Adrian L. Harris |
Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies
|
EP2537532A1
(de)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
|
WO2012175711A1
(en)
|
2011-06-24 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy
|
ME02632B
(de)
|
2011-06-28 |
2017-06-20 |
Oxford Biotherapeutics Ltd |
Therapeutisches und diagnostisches ziel
|
EP3357511B1
(de)
|
2011-06-30 |
2020-05-13 |
Genzyme Corporation |
Inhibitoren der t-zell-aktivierung
|
CA2840552A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
US20140148390A1
(en)
|
2011-07-08 |
2014-05-29 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
EP2734236A4
(de)
|
2011-07-13 |
2015-04-15 |
Abbvie Inc |
Verfahren und zusammensetzungen zur behandlung von asthma mit anti-il-13-antikörpern
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
EP2548891A1
(de)
|
2011-07-18 |
2013-01-23 |
Universiteit Maastricht |
Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
|
US20150125533A1
(en)
|
2011-07-25 |
2015-05-07 |
American University In Cairo |
Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
|
US9580485B2
(en)
|
2011-07-27 |
2017-02-28 |
Philogen S.P.A. |
IL-12 immunoconjugate
|
EP2739975B1
(de)
|
2011-08-03 |
2015-06-17 |
Quidel Corporation |
N-acetyl-d-glucosamin für verbesserte spezifität von streptokokken in einem immunoassay
|
US20140242085A1
(en)
|
2011-08-12 |
2014-08-28 |
Medical & Biological Laboratories Co., Ltd. |
Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
EP2759551B1
(de)
|
2011-09-21 |
2019-05-22 |
Fujirebio Inc. |
Antikörper die an einen affinitätskomplex binden der 25oh-vitamin d2 oder d3 und einen dagegen gerichteten antikörper enthält
|
AU2012310328A1
(en)
|
2011-09-23 |
2014-04-10 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. |
Anti-Tumor Necrosis Factor-alpha agents and uses thereof
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
EP2760886B1
(de)
|
2011-09-26 |
2019-10-02 |
Philogen S.p.A. |
Immunocytokin-kombinationstherapie
|
WO2013049362A2
(en)
|
2011-09-27 |
2013-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
|
CA2850549C
(en)
|
2011-09-30 |
2023-03-14 |
Teva Pharmaceuticals Australia Pty Ltd. |
Antibodies against tl1a and uses thereof
|
DK2764093T3
(en)
|
2011-10-05 |
2018-07-30 |
Univ Rockefeller |
DIMER BACTERYPHAGE LYSINES
|
JP6239517B2
(ja)
|
2011-10-10 |
2017-11-29 |
メディミューン リミテッド |
関節リウマチの治療法
|
US20140271657A1
(en)
|
2011-10-12 |
2014-09-18 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
CA2852800A1
(en)
|
2011-10-21 |
2013-04-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
|
ES2784146T3
(es)
|
2011-10-21 |
2020-09-22 |
Pfizer |
Adición de hierro para mejorar el cultivo celular
|
MX2014004977A
(es)
|
2011-10-24 |
2014-09-11 |
Abbvie Inc |
Inmunoaglutinantes dirigidos contra esclerostina.
|
US9265817B2
(en)
|
2011-10-28 |
2016-02-23 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
EP2773777B1
(de)
|
2011-10-31 |
2020-05-13 |
University of Utah Research Foundation |
Genetische veränderungen bei glioblastomen
|
EP2773667A1
(de)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49-antikörper
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
JP2014533247A
(ja)
|
2011-11-01 |
2014-12-11 |
バイオノミクス インコーポレイテッド |
抗体および癌を治療する方法
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
US20140286965A1
(en)
|
2011-11-07 |
2014-09-25 |
Inserm |
Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
|
CA3161431A1
(en)
|
2011-11-07 |
2013-05-16 |
Medimmune Limited |
Combination therapies using anti-pseudomonas psl and pcrv binding molecules
|
EP2776022A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
EP2776838A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Frühe diagnose neurodegenerativer erkrankungen
|
PT2776466T
(pt)
|
2011-11-11 |
2017-11-30 |
Ucb Biopharma Sprl |
Anticorpos de ligação a albumina e seus fragmentos de ligação
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
AU2012340174A1
(en)
|
2011-11-16 |
2014-05-29 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant VIII related disorders
|
SI2780039T1
(en)
|
2011-11-17 |
2018-06-29 |
Pfizer Inc. |
Cytotoxic peptides and their conjugates between the antibody and the drug
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
EP2786156A2
(de)
|
2011-11-30 |
2014-10-08 |
AbbVie Deutschland GmbH & Co KG |
Verfahren und zusammensetzungen zur bestimmung des ansprechens auf eine behandlung mit einem tnf-alpha-hemmer
|
EP2599496A1
(de)
|
2011-11-30 |
2013-06-05 |
Kenta Biotech AG |
Neuartige Targets von Acinetobacter baumannii
|
TWI640537B
(zh)
|
2011-12-05 |
2018-11-11 |
X 染色體有限公司 |
PDGF受體β結合多肽
|
WO2013088136A1
(en)
|
2011-12-12 |
2013-06-20 |
Ahrens Susan |
Ligand for dngr-1 receptor
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
US20150023989A1
(en)
|
2011-12-14 |
2015-01-22 |
Seattle Genetics, Inc. |
New antibody drug conjugates (adcs) and the use thereof
|
GB201121564D0
(en)
|
2011-12-14 |
2012-01-25 |
Queen Mary & Westfield College |
Use of antibody
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
EP2800583A1
(de)
|
2012-01-02 |
2014-11-12 |
Novartis AG |
Cdcp1 und brustkrebs
|
KR102104686B1
(ko)
|
2012-01-10 |
2020-04-24 |
바이오젠 엠에이 인코포레이티드 |
뇌혈관 장벽을 통한 치료학적 분자의 수송 개선법
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
MY176695A
(en)
|
2012-01-27 |
2020-08-19 |
Abbvie Inc |
Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
|
WO2013119990A2
(en)
|
2012-02-10 |
2013-08-15 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
PT2814844T
(pt)
|
2012-02-15 |
2017-09-18 |
Novo Nordisk As |
Anticorpos que se ligam e bloqueiam recetor de acionamento expresso em células mieloides-1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
SI2814842T1
(sl)
|
2012-02-15 |
2018-10-30 |
Novo Nordisk A/S |
Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
JP6407726B2
(ja)
|
2012-03-01 |
2018-10-24 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
長寿命ポリペプチド結合分子
|
EP2828291A1
(de)
|
2012-03-21 |
2015-01-28 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Aus der d1-domäne von nkp46 abgeleitete peptide
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
CN109880867A
(zh)
|
2012-03-27 |
2019-06-14 |
弗·哈夫曼-拉罗切有限公司 |
用于重组蛋白质的改进的收获操作
|
TWI605060B
(zh)
|
2012-03-28 |
2017-11-11 |
賽諾菲公司 |
抗緩激肽b1受體配位體之抗體
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
KR20200105524A
(ko)
|
2012-04-02 |
2020-09-07 |
버그 엘엘씨 |
조사적 세포 기반 분석 및 이의 사용
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013152352A1
(en)
|
2012-04-06 |
2013-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Live, attenuated rubella vector to express vaccine antigens
|
WO2013155447A1
(en)
|
2012-04-13 |
2013-10-17 |
Children's Medical Center Corporation |
Tiki inhibitors
|
IN2014MN02274A
(de)
|
2012-04-17 |
2015-08-07 |
Mayo Foundation |
|
US9212361B2
(en)
|
2012-04-19 |
2015-12-15 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods and pharmaceutical compositions for the treatment of hypertension
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
MX360109B
(es)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Metodos y medios para la produccion de moleculas de tipo ig.
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
EP2844668A1
(de)
|
2012-05-03 |
2015-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung und diagnose von anämie im zusammenhang mit entzündungen
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
US9273140B2
(en)
|
2012-05-10 |
2016-03-01 |
Fujita Health University |
Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
|
WO2013168820A1
(ja)
|
2012-05-11 |
2013-11-14 |
公益財団法人微生物化学研究会 |
抗cxadr抗体
|
EP2847368B1
(de)
|
2012-05-11 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Oberflächenverankertes leichtketten-köder-antikörperdisplaysystem
|
WO2013173364A2
(en)
|
2012-05-14 |
2013-11-21 |
Biogen Idec Ma Inc. |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
KR102433686B1
(ko)
|
2012-05-15 |
2022-08-19 |
씨젠 인크. |
자가-안정화 링커 접합체
|
JP6122948B2
(ja)
|
2012-05-15 |
2017-04-26 |
モルフォテック, インコーポレイテッド |
胃癌の治療のための方法
|
WO2013171296A1
(en)
|
2012-05-16 |
2013-11-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Diagnostic and treatment of sarcoidosis
|
WO2013177115A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
CN104603149B
(zh)
|
2012-05-24 |
2017-06-30 |
万机集团有限公司 |
与预防和治疗狂犬病感染相关的组合物和方法
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
SI2858647T1
(sl)
|
2012-06-08 |
2018-11-30 |
Sensorion |
Inhibitorji receptorja H4 za zdravljenje tinitusa
|
JP2015521589A
(ja)
|
2012-06-08 |
2015-07-30 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
プロコアグラント化合物
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(de)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
WO2014011908A1
(en)
|
2012-07-11 |
2014-01-16 |
Esperion Therapeutics, Inc. |
Apolipoprotein mixtures
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
US9840552B2
(en)
|
2012-07-30 |
2017-12-12 |
National University Corporation Nagoya University |
Monoclonal antibody against human midkine
|
WO2014020293A1
(en)
|
2012-07-31 |
2014-02-06 |
Imperial Innovations Limited |
Assay
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2692357A1
(de)
|
2012-08-03 |
2014-02-05 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Neuartige Anti-Plasmodium-Parasiten-Antikörper
|
MX359817B
(es)
|
2012-08-16 |
2018-10-11 |
Ipierian Inc |
Anticuerpos que se enlazan a tau.
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
AU2013316441B2
(en)
|
2012-09-13 |
2018-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Gene knock-in non-human animal
|
WO2014043518A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
MX2015003541A
(es)
|
2012-09-19 |
2015-10-26 |
Abbvie Biotherapeutics Inc |
Metodos para identificar los anticuerpos con inmunogenia reducida.
|
EP2898329B1
(de)
|
2012-09-24 |
2017-05-17 |
Ventana Medical Systems, Inc. |
Verfahren zur identifizierung von auf behandlung ansprechendem nichtkleinzelligem lungenkrebs unter verwendung anaplastischer lymphomkinase als marker
|
SI2900694T1
(sl)
|
2012-09-27 |
2018-12-31 |
Merus N.V. |
Bispecifična IGG protitelesa kot vključitelji T-celic
|
EP2900245A1
(de)
|
2012-09-28 |
2015-08-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von kardiovaskulärer fibrose
|
NO2760138T3
(de)
|
2012-10-01 |
2018-08-04 |
|
|
US9695232B2
(en)
|
2012-10-03 |
2017-07-04 |
Philogen S.P.A. |
Anti-ED-A immunoconjugates for inflammatory bowel disease
|
EP2903692B1
(de)
|
2012-10-08 |
2019-12-25 |
St. Jude Children's Research Hospital |
Therapien auf der basis der steuerung der stabilität und funktion regulatorischer t-zellen über eine neuropilin-1:semaphorin-achse
|
KR102308915B1
(ko)
|
2012-10-15 |
2021-10-06 |
메디뮨 리미티드 |
아밀로이드 베타에 대한 항체
|
EP3722320A3
(de)
|
2012-10-25 |
2020-12-30 |
Bioverativ USA Inc. |
Anti-komplement-c1s-antikörper und verwendungen davon
|
WO2014064192A1
(en)
|
2012-10-26 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
|
JP6543572B2
(ja)
|
2012-11-02 |
2019-07-10 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
抗補体C1s抗体とそれらの用途
|
PT2917195T
(pt)
|
2012-11-05 |
2018-02-09 |
Pfizer |
Análogos de spliceostatina
|
EP2917240A1
(de)
|
2012-11-07 |
2015-09-16 |
Pfizer Inc. |
Antikörper gegen notch-3 und antikörper-wirkstoff-konjugate
|
LT2918603T
(lt)
|
2012-11-08 |
2018-10-25 |
University Of Miyazaki |
Antikūnas, galintis specifiškai atpažinti transferino receptorių
|
GB201220924D0
(en)
|
2012-11-21 |
2013-01-02 |
Cancer Res Inst Royal |
Materials and methods for determining susceptibility or predisposition to cancer
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
WO2014100139A1
(en)
|
2012-12-18 |
2014-06-26 |
The Rockefeller University |
Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
WO2014100602A1
(en)
|
2012-12-20 |
2014-06-26 |
Hospital For Special Surgery |
Treatment of egf-receptor dependent pathologies
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
US11211167B2
(en)
|
2012-12-28 |
2021-12-28 |
Ventana Medical Systems, Inc. |
Image analysis for breast cancer prognosis
|
CA2899960C
(en)
|
2013-02-01 |
2022-05-03 |
Transbio Ltd |
Anti-cd83 antibodies and use thereof
|
US9340618B2
(en)
|
2013-02-07 |
2016-05-17 |
Csl Limited |
IL-11R binding proteins
|
US9932396B2
(en)
|
2013-02-08 |
2018-04-03 |
Medical & Biological Laboratories Co., Ltd. |
Antibody against human NRG1 protein
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2956480B1
(de)
|
2013-02-13 |
2019-09-04 |
Laboratoire Français du Fractionnement et des Biotechnologies |
In hohem masse galactosylierte anti-tnf-alpha-antikörper und verwendungen davon
|
BR112015019348A2
(pt)
|
2013-02-13 |
2017-08-22 |
Lab Francais Du Fractionnement |
Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
|
EP3339327A3
(de)
|
2013-02-28 |
2018-09-19 |
National Cancer Center |
Antikörper gegen unlösliches fibrin
|
WO2014164472A1
(en)
|
2013-03-10 |
2014-10-09 |
The Board Of Regents Of The University Of Texas System |
Biomarkers for chagas disease related cardiomyopathy
|
EP2830651A4
(de)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
|
KR102241868B1
(ko)
|
2013-03-13 |
2021-04-20 |
사노피 |
항-cd38 항체 및 카르필조밉을 포함하는 조성물
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
US10023608B1
(en)
|
2013-03-13 |
2018-07-17 |
Amgen Inc. |
Protein purification methods to remove impurities
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズAbbott Laboratories |
Hcvコア脂質結合ドメインモノクローナル抗体
|
US10081673B2
(en)
|
2013-03-14 |
2018-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
SG11201504260UA
(en)
|
2013-03-14 |
2015-10-29 |
Abbvie Inc |
Low acidic species compositions and methods for producing and using the same
|
EP2968526A4
(de)
|
2013-03-14 |
2016-11-09 |
Abbott Lab |
Hcv-antigen-antikörper-kombinationstest sowie verfahren und zusammensetzungen zur verwendung darin
|
WO2014159554A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズAbbott Laboratories |
改良された抗体検出のためのhcvns3組換え抗原およびこの突然変異体
|
CN105143257B
(zh)
|
2013-03-15 |
2020-10-27 |
艾伯维生物医疗股份有限公司 |
Fc变体
|
MY174813A
(en)
|
2013-03-15 |
2020-05-16 |
Zymeworks Inc |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
RU2015144033A
(ru)
|
2013-03-15 |
2017-04-26 |
Эббви Байотекнолоджи Лтд. |
Антитела против cd25 и их применения
|
ES2731232T3
(es)
|
2013-03-15 |
2019-11-14 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio
|
JP2016515524A
(ja)
|
2013-03-15 |
2016-05-30 |
アッヴィ バイオテクノロジー リミテッド |
抗cd25抗体およびそれらの使用
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
EP2976362B1
(de)
|
2013-03-19 |
2019-10-23 |
Beijing Shenogen Pharma Group Ltd. |
Antikörper und verfahren zur behandlung von östrogenrezeptor-assoziierten erkrankungen
|
EP2976085A1
(de)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von chronischen lebererkrankungen im zusammenhang mit einer niedrigen hepcidinexpression
|
WO2014167083A1
(en)
|
2013-04-12 |
2014-10-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for predicting the risk of developing a colonic neoplasia
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
SG10201913751RA
(en)
|
2013-05-06 |
2020-03-30 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
GB201308259D0
(en)
|
2013-05-08 |
2013-06-12 |
Iles Raymond K |
Cancer diagnosis and monitoring
|
JP6416224B2
(ja)
|
2013-05-17 |
2018-10-31 |
セントル ナショナル デ ラ ルシュルシュ サイエンティフィーク(シーエヌアールエス) |
抗cxcl1抗体、抗cxcl7抗体および抗cxcl8抗体ならびにそれらの用途
|
AU2014268298B2
(en)
|
2013-05-24 |
2019-01-17 |
Medlmmune, Llc |
Anti-B7-H5 antibodies and their uses
|
SG11201509982UA
(de)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
PL3007726T3
(pl)
|
2013-06-10 |
2021-01-11 |
Ipierian, Inc. |
Metody leczenia tauopatii
|
RU2016100892A
(ru)
|
2013-06-14 |
2017-07-19 |
Байер Фарма Акциенгезельшафт |
Антитела против tweakr и их применение
|
EP3159695A3
(de)
|
2013-06-20 |
2017-07-05 |
The Trustees of The University of Pennsylvania |
Verfahren zur diagnose von bauchspeicheldrüsenkrebs
|
US10221239B2
(en)
|
2013-06-28 |
2019-03-05 |
Singapore Health Services Pte Ltd |
TRPM4 channel inhibitors for stroke treatment
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
US9919029B2
(en)
|
2013-07-26 |
2018-03-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
US20160178610A1
(en)
|
2013-08-07 |
2016-06-23 |
Friedrich Miescher Institute For Biomedical Research |
New screening method for the treatment Friedreich's ataxia
|
SG10201710013RA
(en)
|
2013-08-13 |
2018-01-30 |
Sanofi Sa |
Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
|
TW201722994A
(zh)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
US10016424B2
(en)
|
2013-09-16 |
2018-07-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of epilepsy
|
AU2014326974B2
(en)
|
2013-09-24 |
2017-01-19 |
The Feinstein Institute For Medical Research |
Peptides inhibiting cold-inducible RNA binding protein activity
|
EP3049085B9
(de)
|
2013-09-26 |
2021-08-18 |
Beth Israel Deaconess Medical Center, Inc. |
Sgk1 inhibitoren bei der behandlung von long-qt-syndrom
|
GB201317207D0
(en)
|
2013-09-27 |
2013-11-13 |
Univ Glasgow |
Materials and methods for modulating disc1 turnover
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
PT3055331T
(pt)
|
2013-10-11 |
2021-04-05 |
Oxford Bio Therapeutics Ltd |
Anticorpos conjugados contra ly75 para o tratamento de cancro
|
US11103593B2
(en)
|
2013-10-15 |
2021-08-31 |
Seagen Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
EP3733868A3
(de)
|
2013-10-28 |
2021-01-13 |
DOTS Technology Corp. |
Allergennachweis
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
US20160264648A1
(en)
|
2013-11-06 |
2016-09-15 |
Osaka University |
Antibody having broad neutralization activity against group 1 influenza a viruses
|
WO2015070068A1
(en)
|
2013-11-07 |
2015-05-14 |
Abbvie Inc. |
Isolation and purification of antibodies
|
EP2871189A1
(de)
|
2013-11-07 |
2015-05-13 |
Institut Pasteur |
Hochaffiner, monoklonaler Anti-Strep-Tag-Antikörper
|
EP3065769A4
(de)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Prokoagulatorische fusionsverbindung
|
GB201320061D0
(en)
|
2013-11-13 |
2013-12-25 |
Electrophoretics Ltd |
Materials nad methods for diagnosis and prognosis of liver cancer
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
JP6629201B2
(ja)
|
2013-11-27 |
2020-01-15 |
アイピエリアン,インコーポレイティド |
タウオパチーの処置方法
|
EP3530286A1
(de)
|
2013-11-28 |
2019-08-28 |
CSL Limited |
Verfahren zur behandlung von diabetischer nephropathie
|
KR20160097294A
(ko)
|
2013-12-09 |
2016-08-17 |
뉴욕 유니버시티 |
항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
|
WO2015086727A2
(en)
|
2013-12-11 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New prognostic method for patients suffering of a cancer
|
US20160333063A1
(en)
|
2013-12-13 |
2016-11-17 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
US9944694B2
(en)
|
2013-12-13 |
2018-04-17 |
Rijksuniversiteit Groningen |
Antibodies against Staphylococcus aureus and uses therof
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
PL3082860T3
(pl)
|
2013-12-18 |
2021-06-14 |
Csl Limited |
Sposób leczenia ran
|
FI3082878T3
(fi)
|
2013-12-19 |
2022-12-15 |
|
Metyleenikarbamaatin linkkerit käytettäviksi kohdennettujen lääkeaineiden konjugaattien kanssa
|
SG11201604758PA
(en)
|
2013-12-23 |
2016-07-28 |
Bayer Pharma AG |
Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
|
TW201609805A
(zh)
|
2013-12-23 |
2016-03-16 |
美國禮來大藥廠 |
結合egfr及met之多功能抗體
|
CA2935077C
(en)
|
2013-12-27 |
2022-03-15 |
Geoffrey C. Winters |
Sulfonamide-containing linkage systems for drug conjugates
|
MY180257A
(en)
|
2014-01-27 |
2020-11-26 |
Pfizer |
Bifunctional cytotoxic agents
|
MX2016010059A
(es)
|
2014-02-04 |
2017-04-27 |
Contrafect Corp |
Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
|
JP6713931B2
(ja)
|
2014-02-11 |
2020-06-24 |
シアトル ジェネティクス,インコーポレイティド |
タンパク質の選択的還元
|
MX2016009862A
(es)
|
2014-02-17 |
2016-10-31 |
Seattle Genetics Inc |
Conjugados de anticuerpo-farmaco hidrofilicos.
|
IL301147A
(en)
|
2014-02-28 |
2023-05-01 |
Merus Nv |
An antibody that binds to ErbB-2 and ErbB-3
|
NZ724013A
(en)
|
2014-02-28 |
2019-11-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
GB201403815D0
(en)
|
2014-03-04 |
2014-04-16 |
Mologic Ltd |
Assay
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
EP3119876A1
(de)
|
2014-03-19 |
2017-01-25 |
Pfizer Inc. |
Verfahren zur zellkultur
|
CA2943242A1
(en)
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
CN106536556B
(zh)
|
2014-04-04 |
2020-02-07 |
生态学有限公司 |
结合lgr5的人源化抗体
|
NZ722668A
(en)
|
2014-04-10 |
2024-02-23 |
Daiichi Sankyo Europe Gmbh |
Anti-her3 antibody-drug conjugate
|
EP3639843A1
(de)
|
2014-04-16 |
2020-04-22 |
Philippe Rouet |
Apoo zur verwendung in einem verfahren zur behandlung von krebs und verschiedenen pathophysiologischen zuständen
|
GB201407132D0
(en)
|
2014-04-23 |
2014-06-04 |
Velgene Biotechnology |
Marker for neurodegenerative disorders
|
US11624093B2
(en)
|
2014-04-24 |
2023-04-11 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
US10308935B2
(en)
|
2014-06-23 |
2019-06-04 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
|
WO2015199976A1
(en)
|
2014-06-24 |
2015-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Target activated microdissection
|
US20170183376A1
(en)
|
2014-06-24 |
2017-06-29 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
TW201628647A
(zh)
|
2014-06-27 |
2016-08-16 |
賽諾菲公司 |
抗-il4-il13雙特異性抗體
|
CN106573038A
(zh)
|
2014-06-30 |
2017-04-19 |
默多克儿童研究所 |
螺杆菌治疗剂
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
SG11201609707WA
(en)
|
2014-07-01 |
2017-01-27 |
Pfizer |
Bispecific heterodimeric diabodies and uses thereof
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
US20160185848A1
(en)
|
2014-07-09 |
2016-06-30 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using sugars
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
MY178347A
(en)
|
2014-07-17 |
2020-10-08 |
Novo Nordisk As |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
|
ES2825708T3
(es)
|
2014-07-17 |
2021-05-17 |
Univ Pennsylvania |
Métodos para usar exosomas para monitorizar el estado de órgano trasplantado
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
WO2016016415A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
ES2726645T3
(es)
|
2014-08-01 |
2019-10-08 |
Inst Nat Sante Rech Med |
Un anticuerpo anti-CD45RC para usar como medicamento
|
JP6796058B2
(ja)
|
2014-08-08 |
2020-12-02 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
インビトロおよびインビボにおける標的の光制御除去
|
EP3185004A4
(de)
*
|
2014-08-20 |
2018-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur messung der viskosität einer proteinlösung
|
US10961506B2
(en)
|
2014-09-04 |
2021-03-30 |
Stemcell Technologies Inc. |
Soluble antibody complexes for T cell or NK cell activation and expansion
|
DK3194421T3
(da)
|
2014-09-17 |
2022-02-14 |
Zymeworks Inc |
Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
|
US10080790B2
(en)
|
2014-09-19 |
2018-09-25 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
US10806773B2
(en)
|
2014-10-09 |
2020-10-20 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable IL-2 dose regimen for treating immune disorders
|
EP3009147A1
(de)
|
2014-10-16 |
2016-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur Behandlung von resistenten Glioblastomen
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
US10870704B2
(en)
|
2014-10-23 |
2020-12-22 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
GB201419108D0
(en)
|
2014-10-27 |
2014-12-10 |
Glythera Ltd |
Materials and methods relating to linkers for use in antibody drug conjugates
|
WO2016066671A1
(en)
|
2014-10-29 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating resistant cancers using progastrin inhibitors
|
SG11201703446RA
(en)
|
2014-10-31 |
2017-05-30 |
Abbvie Biotherapeutics Inc |
Anti-cs1 antibodies and antibody drug conjugates
|
EP4183806A3
(de)
|
2014-11-12 |
2023-08-02 |
Seagen Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
GB201420852D0
(en)
|
2014-11-24 |
2015-01-07 |
Genevillage Kft |
Method
|
BR112017012377A2
(pt)
|
2014-12-09 |
2018-04-24 |
Abbvie Inc |
conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula
|
CA2970155A1
(en)
|
2014-12-09 |
2016-06-16 |
Abbvie Inc. |
Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
|
EP3229838B1
(de)
|
2014-12-11 |
2020-09-09 |
Pierre Fabre Medicament |
Anti-c10orf54-antikörper und verwendungen davon
|
CA2967224C
(en)
|
2014-12-11 |
2023-08-22 |
Inbiomotion S.L. |
Binding members for human c-maf
|
EP3233127A1
(de)
|
2014-12-15 |
2017-10-25 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
EP3789039A1
(de)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk-antikörper und verwendungen davon
|
PT3240801T
(pt)
|
2014-12-31 |
2021-02-18 |
Checkmate Pharmaceuticals Inc |
Imunoterapia antitumoral combinada
|
MX2017009038A
(es)
|
2015-01-08 |
2017-10-25 |
Biogen Ma Inc |
Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
|
CA2916283A1
(en)
|
2015-01-09 |
2016-07-09 |
Pfizer Inc. |
Dosage regimen for madcam antagonists
|
SG11201705986QA
(en)
|
2015-01-29 |
2017-08-30 |
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa |
Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
|
GB201501613D0
(en)
|
2015-01-30 |
2015-03-18 |
Ucb Biopharma Sprl |
Treatment of autoimmune disorders with CD154 antibodies
|
WO2016139482A1
(en)
|
2015-03-03 |
2016-09-09 |
Kymab Limited |
Antibodies, uses & methods
|
EP3265825A4
(de)
|
2015-03-06 |
2018-08-08 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2-biomarker zur vorhersage von pd-1-weg-inhibitor-reaktionen bei ösophagogastrischem krebs
|
EP3265483B1
(de)
|
2015-03-06 |
2019-12-11 |
CSL Behring Lengnau AG |
Modifizierter von-willebrand-faktor mit verbesserter halbwertzeit
|
GB201503967D0
(en)
|
2015-03-09 |
2015-04-22 |
Univ Glasgow |
Biocompatible implants for use in tendon therapy
|
WO2016146587A1
(en)
|
2015-03-13 |
2016-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Hepcidin antagonists for use in the treatment of inflammation
|
WO2016149368A1
(en)
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
WO2016151432A1
(en)
|
2015-03-20 |
2016-09-29 |
Pfizer Inc. |
Bifunctional cytotoxic agents containing the cti pharmacophore
|
LT3274370T
(lt)
|
2015-03-23 |
2020-02-10 |
Bayer Pharma Aktiengesellschaft |
Antikūnai prieš ceacam6 ir jų panaudojimas
|
RS63956B1
(sr)
|
2015-04-06 |
2023-02-28 |
Bioverativ Usa Inc |
Humanizovana anti-c1s antitela i metode njihove upotrebe
|
EP3078378B1
(de)
|
2015-04-08 |
2020-06-24 |
Vaiomer |
Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie
|
EP3078675A1
(de)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induktionsdosierschema zur behandlung von krankheiten die von tnf alpha verursacht sind
|
EP3081575A1
(de)
|
2015-04-12 |
2016-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti-plasmodium-parasiten-antikörper
|
EP4276116A3
(de)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispezifische antikörperkonstrukte für cdh3 und cd3
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
WO2016179518A2
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
SG11201708804WA
(en)
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
WO2016185026A1
(en)
|
2015-05-20 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for modulation polarization and activation of macrophages
|
WO2016189104A1
(en)
|
2015-05-27 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to produce t cells
|
HUE048284T2
(hu)
|
2015-05-29 |
2020-07-28 |
Abbvie Inc |
Anti-CD40 antitestek és alkalmazásuk
|
SG10201913500TA
(en)
|
2015-05-29 |
2020-03-30 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
US10723793B2
(en)
|
2015-06-12 |
2020-07-28 |
Ludwig Institute For Cancer Research, Ltd. |
TGF-β3 specific antibodies and methods and uses thereof
|
ES2909486T3
(es)
|
2015-06-19 |
2022-05-06 |
Centurion Biopharma Corp |
Sistemas de administración para liberación controlada de fármaco
|
MX2017017172A
(es)
|
2015-06-22 |
2018-02-23 |
Bayer Pharma AG |
Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
|
WO2016207094A1
(de)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
|
CA2990411A1
(en)
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
|
KR20180020225A
(ko)
|
2015-06-23 |
2018-02-27 |
바이엘 파마 악티엔게젤샤프트 |
Ksp 억제제의 표적화된 접합체
|
GB201511196D0
(en)
|
2015-06-25 |
2015-08-12 |
Cytosystems Ltd |
Monoclonal antibodies
|
EP3314250A4
(de)
|
2015-06-26 |
2018-12-05 |
Beth Israel Deaconess Medical Center, Inc. |
Auf tetraspanin 33 (tspann33) in myeloidabgeleiteten suppressorzellen abzielende krebstherapie
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
MA41669A1
(fr)
|
2015-07-06 |
2018-05-31 |
Ucb Biopharma Sprl |
Anticorps se liant a tau
|
US10287343B2
(en)
|
2015-07-06 |
2019-05-14 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
CN108026174B
(zh)
|
2015-07-10 |
2023-02-17 |
美勒斯公司 |
人cd3结合抗体
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
WO2017023861A1
(en)
|
2015-08-03 |
2017-02-09 |
The Regents Of The University Of California |
Compositions and methods for modulating abhd2 activity
|
WO2018036117A1
(zh)
|
2016-08-22 |
2018-03-01 |
复旦大学 |
靶向于组织因子的抗体、其制备方法和用途
|
EA201890630A1
(ru)
|
2015-09-01 |
2018-10-31 |
Эйдженус Инк. |
Антитела против pd-1 и способы их применения
|
EP3798234A1
(de)
|
2015-09-02 |
2021-03-31 |
Immutep S.A.S. |
Agonistische anti-lag-3 antikörper
|
LT3350220T
(lt)
|
2015-09-15 |
2021-09-27 |
Scholar Rock, Inc. |
Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
|
WO2017051347A2
(en)
|
2015-09-23 |
2017-03-30 |
Pfizer Inc. |
Cells and method of cell culture
|
EP3650468A1
(de)
|
2015-09-29 |
2020-05-13 |
Fundació Institut de Recerca Biomèdica (IRB Barcelona) |
Targeting von metastasestammzellen durch einen fettsäurerezeptor (cd36)
|
WO2017060322A2
(en)
|
2015-10-10 |
2017-04-13 |
Bayer Pharma Aktiengesellschaft |
Ptefb-inhibitor-adc
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
AU2016340764B2
(en)
|
2015-10-23 |
2023-06-01 |
Fundació lnstitut de Recerca Biomèdica (IRB Barcelona) |
Binding molecules that inhibit cancer growth
|
US20180348224A1
(en)
|
2015-10-28 |
2018-12-06 |
Friedrich Miescher Institute For Biomedical Resear Ch |
Tenascin-w and biliary tract cancers
|
US10618935B2
(en)
|
2015-11-03 |
2020-04-14 |
Industrial Technology Research Institute |
Antibody-drug conjugate (ADC) and method for forming the same
|
IL258768B2
(en)
|
2015-11-12 |
2023-11-01 |
Siamab Therapeutics Inc |
Compounds interacting with glycans and methods of use
|
WO2017085566A1
(en)
|
2015-11-20 |
2017-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for increase/induction of immune responses
|
GB201520567D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520542D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520548D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520579D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520536D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520564D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520592D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520566D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520583D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520603D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520575D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520563D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520565D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
WO2017089786A1
(en)
|
2015-11-23 |
2017-06-01 |
Immunocore Limited |
Peptides
|
GB201520541D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520562D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520558D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520559D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201607534D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520597D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520539D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
GB201604468D0
(en)
|
2016-03-16 |
2016-04-27 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520589D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520546D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201607535D0
(en)
|
2016-04-29 |
2016-06-15 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520545D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520595D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520557D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520544D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520543D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
GB201520570D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
WO2017095808A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
EP3383429B1
(de)
|
2015-11-30 |
2020-10-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Nmdar antagonisten zur behandlung von krebs angiogenese
|
JP2019500327A
(ja)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
KR20180100122A
(ko)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
AU2016365318B2
(en)
|
2015-12-02 |
2024-04-18 |
Board Of Regents, The University Of Texas System |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
AU2016363013B2
(en)
|
2015-12-04 |
2022-03-10 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
US11007251B2
(en)
|
2015-12-17 |
2021-05-18 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
EP3184544A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein-v-inhibitoren zur verwendung als koagulansien
|
CN109071645A
(zh)
|
2016-01-08 |
2018-12-21 |
供石公司 |
抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
|
WO2017121880A1
(en)
|
2016-01-15 |
2017-07-20 |
Philogen S.P.A |
Intestinal antigens for pharmacodelivery applications
|
CA3012960A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
KR20180103084A
(ko)
|
2016-02-03 |
2018-09-18 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
EP3411404B1
(de)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma- und cd3-bispezifische t-zellaktivierende antikörperkonstrukte
|
EP3207937A1
(de)
|
2016-02-17 |
2017-08-23 |
Royal College of Surgeons in Ireland |
Verfahren zur behandlung oder prävention von sepsis
|
EP4299586A3
(de)
|
2016-03-02 |
2024-04-03 |
Idexx Laboratories, Inc. |
Verfahren und zusammensetzungen zur erkennung und diagnose von nierenerkrankungen und parodontalerkrankungen
|
US11014088B2
(en)
|
2016-03-09 |
2021-05-25 |
The Board Of Regents Of The University Of Texas System |
Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
|
WO2017156263A1
(en)
|
2016-03-09 |
2017-09-14 |
Memorial Sloan-Kettering Cancer Center |
Enigma and cdh18 as companion diagnostics for cdk4 inhibitors
|
PL3365368T3
(pl)
|
2016-03-11 |
2023-08-21 |
Scholar Rock, Inc. |
Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
|
RS61374B1
(sr)
|
2016-03-17 |
2021-02-26 |
Tillotts Pharma Ag |
Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
|
LT3219727T
(lt)
|
2016-03-17 |
2021-02-10 |
Tillotts Pharma Ag |
Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
|
US10774140B2
(en)
|
2016-03-17 |
2020-09-15 |
Numab Therapeutics AG |
Anti-TNFα-antibodies and functional fragments thereof
|
WO2017158084A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
KR102392746B1
(ko)
|
2016-03-17 |
2022-04-29 |
누맙 이노베이션 아게 |
항-TNFα-항체 및 이의 기능성 단편
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
WO2017161976A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
SG11201808167VA
(en)
|
2016-03-24 |
2018-10-30 |
Bayer Pharma AG |
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
|
WO2017162555A1
(en)
|
2016-03-24 |
2017-09-28 |
Bayer Pharma Aktiengesellschaft |
Radio-pharmaceutical complexes
|
AU2017237186A1
(en)
|
2016-03-25 |
2018-11-01 |
Seagen Inc. |
Process for the preparation of PEGylated drug-linkers and intermediates thereof
|
EP3436610A1
(de)
|
2016-03-29 |
2019-02-06 |
Geltor, Inc. |
Expression von proteinen in gramnegativen bakterien mit verhältnis von periplasmatischem volumen zu zytoplasmatischem volumen zwischen 0,5:1 und 10:1
|
BR112018070357A2
(pt)
|
2016-04-04 |
2019-01-29 |
Bioverativ Usa Inc |
anticorpos anticomplemento contra o fator bb e seus usos
|
SG11201808356UA
(en)
|
2016-04-05 |
2018-10-30 |
Pfizer |
Cell culture process
|
JP7281795B2
(ja)
|
2016-04-07 |
2023-05-26 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
|
CN116333140A
(zh)
|
2016-04-08 |
2023-06-27 |
埃缇健康公司D/B/A泽尔拜尔 |
网蛋白-1结合抗体及其用途
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
WO2017182834A1
(en)
|
2016-04-19 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating resistant glioblastoma
|
EP3448391A4
(de)
|
2016-04-27 |
2019-12-18 |
AbbVie Inc. |
Verfahren zur behandlung von erkrankungen mit schädlicher il-13 aktivität unter verwendung von anti-il-13-antikörpern
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
SG11201810040WA
(en)
|
2016-05-11 |
2018-12-28 |
Amgen Inc |
Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
|
KR20230028574A
(ko)
|
2016-05-17 |
2023-02-28 |
애브비 바이오테라퓨틱스 인크. |
항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법
|
AU2017271385B2
(en)
|
2016-05-25 |
2023-10-05 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-MAF status
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
WO2017203051A1
(en)
|
2016-05-26 |
2017-11-30 |
University College Cork - National University Of Ireland, Cork |
An engineered gram positive bacterium
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
MX2018014387A
(es)
|
2016-05-27 |
2019-03-14 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
JP2019523221A
(ja)
|
2016-05-27 |
2019-08-22 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗cd40抗体とその使用
|
EP3464367B1
(de)
|
2016-05-27 |
2020-09-09 |
AbbVie Biotherapeutics Inc. |
Bispezifische bindungsproteine, die ein immunmodulatorisches protein und ein tumorantigen binden
|
WO2017208018A1
(en)
|
2016-06-02 |
2017-12-07 |
Immunocore Limited |
Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
|
EP3468599A2
(de)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98-antikörper und antikörperwirkstoffkonjugate
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CA3027103A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
WO2017214335A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109562170B
(zh)
|
2016-06-08 |
2023-01-13 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
MX2018015340A
(es)
|
2016-06-10 |
2019-03-28 |
Bayer Pharma AG |
Complejos radio-farmaceuticos.
|
MX2018015584A
(es)
|
2016-06-13 |
2019-09-18 |
I Mab |
Anticuerpos anti-pd-l1 y usos de los mismos.
|
JP7022707B2
(ja)
|
2016-06-15 |
2022-02-18 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ksp阻害剤および抗cd123抗体を含む特異的抗体-薬物-コンジュゲート(adc)
|
WO2017216352A1
(en)
|
2016-06-16 |
2017-12-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of gut inflammatory diseases such as inflammatory bowel diseases (ibd) or irritable bowel syndrome (ibs)
|
BR112018076519A8
(pt)
|
2016-06-20 |
2022-07-12 |
F Star Delta Ltd |
Moléculas de ligação que se ligam a pd-l1 e lag-3
|
KR20190039937A
(ko)
|
2016-07-08 |
2019-04-16 |
스태튼 바이오테크놀로지 비.브이. |
항-ApoC3 항체 및 이의 사용 방법
|
KR102565885B1
(ko)
|
2016-07-20 |
2023-08-09 |
유니버시티 오브 유타 리서치 파운데이션 |
Cd229 car t 세포 및 이의 사용 방법
|
GB201613167D0
(en)
|
2016-07-29 |
2016-09-14 |
Univ Southampton |
Cancer and b-cell related disease therapy
|
JP2018058822A
(ja)
|
2016-08-03 |
2018-04-12 |
ファイザー・インク |
ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
|
MA45945A
(fr)
|
2016-08-09 |
2019-06-19 |
Seattle Genetics Inc |
Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
|
CN106938051B
(zh)
|
2016-08-22 |
2019-10-11 |
复旦大学 |
靶向于组织因子的抗体-药物偶联物
|
US20190202907A1
(en)
|
2016-09-02 |
2019-07-04 |
180 Therapeutics Lp |
Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
|
EP3570865A4
(de)
|
2016-09-02 |
2020-05-20 |
180 Therapeutics LP |
Verfahren zur behandlung einer lokalisierten fibrotischen erkrankung unter verwendung eines bispezifischen il-33/tnf-antikörpers
|
EP3293271A1
(de)
|
2016-09-12 |
2018-03-14 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Marker und target als eine diagnosevariable und target zur therapie von metastatischem krebs
|
HUE051700T2
(hu)
|
2016-09-14 |
2021-03-29 |
Abbvie Biotherapeutics Inc |
Anti-PD-1 antitestek
|
JP7256116B2
(ja)
|
2016-09-19 |
2023-04-11 |
アイ-エムエービー バイオファーマ (ハンジョウ) カンパニー リミテッド |
抗gm-csf抗体およびその使用
|
JP7466308B2
(ja)
|
2016-09-20 |
2024-04-12 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Usp10バイオマーカーおよびモジュレーターを用いたamlの同定、評価、予防および処置のための組成物および方法
|
RU2759334C2
(ru)
|
2016-09-21 |
2021-11-12 |
Нексткьюр, Инк. |
Антитела против siglec-15 и способы их применения
|
CN110023339A
(zh)
|
2016-09-23 |
2019-07-16 |
Csl有限公司 |
凝血因子结合蛋白及其应用
|
CA3038909A1
(en)
|
2016-09-29 |
2018-04-05 |
Amgen Inc. |
Low-viscosity antigen binding proteins and methods of making them
|
TW202246349A
(zh)
|
2016-10-11 |
2022-12-01 |
美商艾吉納斯公司 |
抗lag-3抗體及其使用方法
|
MX2019004259A
(es)
|
2016-10-12 |
2019-09-27 |
Bioverativ Usa Inc |
Anticuerpos anti-c1s y metodos de uso de los mismos.
|
IL291810A
(en)
|
2016-10-18 |
2022-06-01 |
Seagen Inc |
Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors
|
MA46673A
(fr)
|
2016-10-26 |
2019-09-04 |
Leap Therapeutics Inc |
Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
WO2018085359A1
(en)
|
2016-11-02 |
2018-05-11 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
EP3318277A1
(de)
|
2016-11-04 |
2018-05-09 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Inhibitoren der glucosylceramidsynthase zur behandlung von motoneuronerkrankungen
|
EP3535288A1
(de)
|
2016-11-07 |
2019-09-11 |
Immunocore Limited |
Peptide
|
WO2018083538A1
(en)
|
2016-11-07 |
2018-05-11 |
Neuracle Scienc3 Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
NZ754407A
(en)
|
2016-11-09 |
2023-01-27 |
Philogen Spa |
Il2 and tnf mutant immunoconjugates
|
EP3541847A4
(de)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycaninteragierende verbindungen und verfahren zur verwendung
|
WO2018098370A1
(en)
|
2016-11-23 |
2018-05-31 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
MX2019006340A
(es)
|
2016-12-07 |
2019-11-07 |
Agenus Inc |
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
|
CA3046082A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
KR20210157471A
(ko)
|
2016-12-15 |
2021-12-28 |
애브비 바이오테라퓨틱스 인크. |
항-ox40 항체 및 이의 용도
|
WO2018115083A1
(en)
|
2016-12-21 |
2018-06-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
|
CN110312533B
(zh)
|
2016-12-21 |
2023-11-03 |
拜耳公司 |
具有酶促可裂解的基团的细胞毒性活性剂的前药
|
WO2018114578A1
(de)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
|
CA3047522A1
(en)
|
2016-12-21 |
2018-06-28 |
Bayer Pharma Aktiengesellschaft |
Specific antibody drug conjugates (adcs) having ksp inhibitors
|
EA201991204A1
(ru)
|
2016-12-22 |
2019-12-30 |
Университа Дельи Студи Манья Греча Катандзаро |
Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43
|
EP3559047A1
(de)
|
2016-12-23 |
2019-10-30 |
Novartis AG |
Faktor xi-antikörper und verfahren zur verwendung
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
FI3565592T3
(fi)
|
2017-01-06 |
2023-05-10 |
Scholar Rock Inc |
Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
|
WO2018129329A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
|
EP3565845A4
(de)
|
2017-01-06 |
2020-10-07 |
Biosion, Inc. |
Erbb2-antikörper und deren verwendungen
|
GB201700345D0
(en)
|
2017-01-09 |
2017-02-22 |
F-Star Beta Ltd |
Conditional agonists of immune responses
|
WO2018132768A1
(en)
|
2017-01-13 |
2018-07-19 |
Sanna Pietro P |
Methods and compositions for treating hpa hyperactivity
|
BR112019013238A2
(pt)
|
2017-01-20 |
2020-02-11 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anticorpos anti-pd-1 e usos dos mesmos
|
US20190345186A1
(en)
|
2017-01-24 |
2019-11-14 |
Pfizer Inc. |
Calicheamicin deratives and antibody drug conjugates thereof
|
CN109476755B
(zh)
|
2017-01-24 |
2020-12-04 |
天境生物科技(上海)有限公司 |
Cd73抗体及其用途
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
MA47812A
(fr)
|
2017-03-03 |
2021-04-14 |
Seagen Inc |
Composés interagissant avec le glycane et méthodes d'utilisation
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
US20210115116A1
(en)
|
2017-03-14 |
2021-04-22 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases and disorders
|
CN111010875B
(zh)
|
2017-03-15 |
2024-04-05 |
库尔生物制药有限公司 |
用于调节免疫应答的方法
|
EP4095161A1
(de)
|
2017-03-15 |
2022-11-30 |
Tsinghua University |
Neuartige anti-trkb-antikörper
|
WO2018167621A1
(en)
|
2017-03-16 |
2018-09-20 |
Pfizer Inc. |
Tyrosine prototrophy
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
US20200330590A1
(en)
|
2017-03-27 |
2020-10-22 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
WO2018181059A1
(ja)
|
2017-03-30 |
2018-10-04 |
日油株式会社 |
ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体
|
EP3604384B1
(de)
|
2017-03-30 |
2021-09-08 |
NOF Corporation |
Hydrophiles polymerderivat mit selbstimmolativem acetallinker und verbundstoff damit
|
EP3600413A1
(de)
|
2017-03-31 |
2020-02-05 |
Merus N.V. |
Erbb-2- und erbb3-bindende bispezifische antikörper zur verwendung bei der behandlung von zellen mit einem ngr1-fusionsgen
|
BR112019017241A2
(pt)
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
CN110506056A
(zh)
|
2017-04-21 |
2019-11-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体和其使用方法
|
SG11201909563VA
(en)
|
2017-04-27 |
2019-11-28 |
Seattle Genetics Inc |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
MA48461A
(fr)
|
2017-04-28 |
2020-03-04 |
Amgen Inc |
Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
|
EP3618863B1
(de)
|
2017-05-01 |
2023-07-26 |
Agenus Inc. |
Anti-tigit antikörper und deren verwendung
|
WO2018204907A1
(en)
|
2017-05-05 |
2018-11-08 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
EP3401328A1
(de)
|
2017-05-10 |
2018-11-14 |
Bayer Pharma Aktiengesellschaft |
Einstufige antikörperhumanisierung durch mischung der rahmenregionen einer golden-gate-basierten keimbahn
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
CA3063344A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Novel cd73 antibody, preparation and uses thereof
|
EP3409297A1
(de)
|
2017-05-30 |
2018-12-05 |
AlfaRim Medial Holding B.V. |
Optimaler 225actinium-213bismut-generator für alpha-partikelradioimmunotherapie
|
EP3630834A1
(de)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
|
EP3630835A1
(de)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
CN110997718B
(zh)
|
2017-06-07 |
2023-11-10 |
菲洛根股份公司 |
血管内皮生长因子/抗纤连蛋白抗体融合蛋白
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
WO2018234538A1
(en)
|
2017-06-23 |
2018-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
|
EP3421607A1
(de)
|
2017-06-29 |
2019-01-02 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Identifizierung und entfernung von geschädigten und/oder seneszenten zellen
|
US20210145828A1
(en)
|
2017-06-29 |
2021-05-20 |
Rutgers, The State University Of New Jersey |
Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
AU2018306436A1
(en)
|
2017-07-27 |
2020-02-13 |
Nomocan Pharmaceuticals Llc |
Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
|
EP3658583A1
(de)
|
2017-07-28 |
2020-06-03 |
Scholar Rock, Inc. |
Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
|
JP6889328B2
(ja)
|
2017-07-31 |
2021-06-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
三次元構造に基づくヒト化方法
|
MX2020001432A
(es)
|
2017-08-09 |
2020-03-20 |
Merus Nv |
Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).
|
EP3444275A1
(de)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoklonaler antikörper anti-fgfr4
|
EP3679070A1
(de)
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Antikörper gegen protein 1 des programmierten zelltods
|
EP3681989A1
(de)
|
2017-09-15 |
2020-07-22 |
Bristol-Myers Squibb Company |
Online-überwachung der biomassekapazität während der grossserienproduktion von polypeptiden von interesse
|
CN111148510A
(zh)
|
2017-09-15 |
2020-05-12 |
美国安进公司 |
用于治疗性蛋白质的冻干药物配制品的方法
|
US20200230266A1
(en)
|
2017-09-20 |
2020-07-23 |
Alfarim Medical Holding B.V. |
The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
EP3693013A4
(de)
|
2017-10-06 |
2021-06-30 |
Ono Pharmaceutical Co., Ltd. |
Bispezifischer antikörper
|
AU2018347796A1
(en)
|
2017-10-10 |
2020-05-07 |
Medicenna Therapeutics, Inc. |
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
US11466073B2
(en)
|
2017-10-18 |
2022-10-11 |
Csl Limited |
Human serum albumin variants and uses thereof
|
CA3080103A1
(en)
|
2017-10-31 |
2019-05-09 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
WO2019089594A1
(en)
|
2017-10-31 |
2019-05-09 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
US11673963B2
(en)
|
2017-11-02 |
2023-06-13 |
Oxford Biotherapeutics Ltd |
CRTAM antibodies and methods of treating cancer
|
WO2019094595A2
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
US11654153B2
(en)
|
2017-11-22 |
2023-05-23 |
Inbiomotion S.L. |
Therapeutic treatment of breast cancer based on c-MAF status
|
EP3713603A1
(de)
|
2017-11-23 |
2020-09-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Neues verfahren zur behandlung einer dengue-virus-infektion
|
WO2019102435A1
(en)
|
2017-11-27 |
2019-05-31 |
Euro-Celtique S.A. |
Humanized antibodies targeting human tissue factor
|
KR20200117988A
(ko)
|
2017-11-30 |
2020-10-14 |
센추리온 바이오파마 코포레이션 |
메이탄시노이드계 약물 전달 시스템
|
CA3083983A1
(en)
|
2017-11-30 |
2019-06-06 |
Centurion Biopharma Corporation |
Albumin-binding prodrugs of auristatin e derivatives
|
EP3724229A1
(de)
|
2017-12-11 |
2020-10-21 |
Amgen Inc. |
Kontinuierliches herstellungsverfahren für bispezifische antikörperprodukte
|
EP3502139A1
(de)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antikörper gegen tumorantigene
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
CN111954541A
(zh)
|
2018-01-25 |
2020-11-17 |
Acm生物实验室私人有限公司 |
包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途
|
WO2019149637A1
(en)
|
2018-01-31 |
2019-08-08 |
Bayer Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
TWI804572B
(zh)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
WO2019157772A1
(zh)
|
2018-02-13 |
2019-08-22 |
和元生物技术(上海)股份有限公司 |
抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
|
EP3755707A1
(de)
|
2018-02-20 |
2020-12-30 |
Seagen Inc. |
Hydrophobe auristatin-f-verbindungen und deren konjugate
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
EP3755712A1
(de)
|
2018-02-21 |
2020-12-30 |
Cell Design Labs, Inc. |
Chimäre transmembranrezeptoren und verwendungen davon
|
US20210002373A1
(en)
|
2018-03-01 |
2021-01-07 |
Nextcure, Inc. |
KLRG1 Binding Compositions and Methods of Use Thereof
|
WO2019170131A1
(zh)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
|
CA3093645A1
(en)
|
2018-03-13 |
2019-09-19 |
Nof Corporation |
Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain
|
CN110272490B
(zh)
|
2018-03-14 |
2021-05-14 |
上海开拓者生物医药有限公司 |
靶向ctla-4抗体、其制备方法和用途
|
KR20200133240A
(ko)
|
2018-03-16 |
2020-11-26 |
브리스톨-마이어스 스큅 컴퍼니 |
단백질 생산 동안의 대사 효소 활성 및 디술피드 결합 환원
|
HRP20230744T1
(hr)
|
2018-03-26 |
2023-10-27 |
Glycanostics S.R.O. |
Sredstva i metode glikoprofiliranja proteina
|
WO2019185792A1
(en)
|
2018-03-29 |
2019-10-03 |
Philogen S.P.A |
Cancer treatment using immunoconjugates and immune check-point inhibitors
|
US11155618B2
(en)
|
2018-04-02 |
2021-10-26 |
Bristol-Myers Squibb Company |
Anti-TREM-1 antibodies and uses thereof
|
CN110343178B
(zh)
|
2018-04-03 |
2022-07-22 |
上海开拓者生物医药有限公司 |
抗人lag-3单克隆抗体及其应用
|
JP2021521273A
(ja)
|
2018-04-12 |
2021-08-26 |
メディアファーマ エス.アール.エル. |
Lgals3bp抗体−薬剤結合体及びがん治療のためのその使用
|
EP3553081A1
(de)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
Natriuretische peptidgepfropfte antikörper im vorhof
|
EP3553079A1
(de)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
Mit natriuretischem peptid vom c-typ gepfropfte antikörper
|
EP3553082A1
(de)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
Natriuretische peptidgepfropfte antikörper im gehirn
|
WO2019209952A2
(en)
|
2018-04-23 |
2019-10-31 |
Emory University |
Vip antagonists and uses in treating cancer
|
WO2019207159A1
(en)
|
2018-04-27 |
2019-10-31 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
CN110483639A
(zh)
|
2018-05-15 |
2019-11-22 |
复旦大学 |
靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
|
KR20210013091A
(ko)
|
2018-05-16 |
2021-02-03 |
시에스엘 리미티드 |
가용성 보체 수용체 1형 변이체 및 이의 용도
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
GB201808927D0
(en)
|
2018-05-31 |
2018-07-18 |
Institute Of Cancer Res Royal Cancer Hospital |
Materials and methods for monitoring the development of resistance of cancers to treatment
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
WO2019236739A1
(en)
|
2018-06-05 |
2019-12-12 |
Amgen Inc. |
Modulating antibody dependent cellular phagocytosis
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
CA3103327A1
(en)
|
2018-06-18 |
2019-12-26 |
Bayer Aktiengesellschaft |
Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
EA202190092A1
(ru)
|
2018-06-21 |
2021-05-18 |
Юманити Терапьютикс, Инк. |
Композиции и способы лечения и профилактики неврологических расстройств
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
WO2020008083A1
(es)
|
2018-07-05 |
2020-01-09 |
Consejo Superior De Investigaciones Científicas |
Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
|
PL3677278T3
(pl)
|
2018-07-11 |
2022-02-28 |
Scholar Rock, Inc. |
Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
|
MX2021000347A
(es)
|
2018-07-11 |
2021-04-19 |
Scholar Rock Inc |
Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
|
WO2020014473A1
(en)
|
2018-07-11 |
2020-01-16 |
Scholar Rock, Inc. |
TGFβ1 INHIBITORS AND USE THEREOF
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
BR112021000394A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
KR20210031479A
(ko)
|
2018-07-12 |
2021-03-19 |
에프-스타 베타 리미티드 |
Cd137 및 ox40에 결합하는 항체 분자
|
CN110713537B
(zh)
|
2018-07-13 |
2023-04-21 |
江苏怀瑜药业有限公司 |
一种sema4d抗体及其制备方法和应用
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
US20210290633A1
(en)
|
2018-07-19 |
2021-09-23 |
INSERM (Insstitut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
CN112512584A
(zh)
|
2018-07-27 |
2021-03-16 |
国立大学法人大阪大学 |
用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物
|
JP2021532140A
(ja)
|
2018-07-30 |
2021-11-25 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cd33及びcd3に結合する二重特異性抗体コンストラクトの長期投与
|
MA53330A
(fr)
|
2018-08-03 |
2021-06-09 |
Amgen Inc |
Constructions d'anticorps pour cldn18.2 et cd3
|
CA3109999A1
(en)
|
2018-08-21 |
2020-02-27 |
Abl Bio Inc. |
Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
|
CA3109732A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
JP2022500371A
(ja)
|
2018-09-11 |
2022-01-04 |
アムジエン・インコーポレーテツド |
抗体依存性細胞介在性細胞傷害の調節方法
|
CN112996539A
(zh)
|
2018-09-12 |
2021-06-18 |
Acm生物实验室私人有限公司 |
包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
|
US10899826B1
(en)
|
2018-09-13 |
2021-01-26 |
Teva Pharmaceuticals International Gmbh |
Pharmaceutical compositions for an anti-CGRP antagonist antibody
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
US20230038521A1
(en)
|
2018-09-21 |
2023-02-09 |
National University Corporation Tokyo Medical An D Dental University |
Human Monoclonal Antibody Binding Specifically to Human Hmgb1, and Pharmaceutical Composition for Treating or Preventing Alzheimer's Disease Containing Said Human Monoclonal Antibody
|
WO2020069303A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Antibodies against soluble bcma
|
AU2019349958A1
(en)
|
2018-09-28 |
2021-05-06 |
Kyowa Kirin Co., Ltd. |
IL-36 antibodies and uses thereof
|
CN112969503A
(zh)
|
2018-10-03 |
2021-06-15 |
斯塔滕生物技术有限公司 |
对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
|
JP2022512636A
(ja)
|
2018-10-11 |
2022-02-07 |
アムジエン・インコーポレーテツド |
二重特異性抗体コンストラクトの下流プロセシング
|
US11674961B2
(en)
|
2018-10-12 |
2023-06-13 |
Quidel Corporation |
Extraction reagent for use in an assay for detection of group A Streptococcus
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
KR20210080465A
(ko)
|
2018-10-23 |
2021-06-30 |
스칼러 락, 인크. |
RGMc-선택적인 억제제 및 그의 용도
|
EP3873944A1
(de)
|
2018-10-31 |
2021-09-08 |
Bayer Aktiengesellschaft |
Umkehrmittel zur neutralisierung der therapeutischen aktivität von anti-fxia-antikörpern
|
EP3873455A1
(de)
|
2018-10-31 |
2021-09-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren zur behandlung von t-helfer-typ-2-vermittelten krankheiten
|
WO2020095104A1
(en)
|
2018-11-05 |
2020-05-14 |
Ludwig Institute For Cancer Research Ltd. |
HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
|
CN113613725A
(zh)
|
2018-11-05 |
2021-11-05 |
路德维格癌症研究所有限公司 |
人源化和变体TGF-β1特异性抗体及其方法和用途
|
US20220259306A1
(en)
|
2018-11-07 |
2022-08-18 |
Shanghai Hyamab Biotech Co., Ltd. |
Nkg2a antibody, preparation method therefor and application thereof
|
CN113348180B
(zh)
|
2018-11-20 |
2023-05-26 |
上海开拓者生物医药有限公司 |
Ox40抗体及其制备方法和应用
|
CN111234018A
(zh)
|
2018-11-29 |
2020-06-05 |
上海开拓者生物医药有限公司 |
全人抗gitr抗体及其制备方法
|
CN111253485A
(zh)
|
2018-11-30 |
2020-06-09 |
上海开拓者生物医药有限公司 |
抗人tim-3单克隆抗体及其应用
|
JP7328658B2
(ja)
|
2018-11-30 |
2023-08-17 |
エービーエル バイオ インコーポレイテッド |
抗pd-l1/抗4-1bb二重特異性抗体およびその使用
|
EP3892637A1
(de)
|
2018-12-03 |
2021-10-13 |
Shanghai Pharmaexplorer Co., Ltd. |
Cd47-antikörper, verfahren zu seiner herstellung und seine verwendungen
|
CA3121884A1
(en)
|
2018-12-06 |
2020-06-11 |
Pfizer Inc. |
Cells with reduced inhibitor production and methods of use thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
EP3896085A4
(de)
|
2018-12-12 |
2022-11-30 |
Shanghai Pharmaexplorer Co., Ltd. |
Monoklonaler antikörper gegen menschliches interleukin 5 (il-5) und dessen verwendung
|
WO2020128927A1
(en)
|
2018-12-20 |
2020-06-25 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
CN111349162A
(zh)
|
2018-12-21 |
2020-06-30 |
神州细胞工程有限公司 |
人源化抗pd-1抗体及其用途
|
CN111434688A
(zh)
|
2019-01-11 |
2020-07-21 |
上海开拓者生物医药有限公司 |
Cd73抗体及其制备方法和应用
|
JP2022522265A
(ja)
|
2019-01-16 |
2022-04-15 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
エリスロフェロンの変異体及びその使用
|
CA3126778A1
(en)
|
2019-01-17 |
2020-07-23 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
|
CA3126727A1
(en)
|
2019-01-28 |
2020-08-06 |
Maple Biotech Llc |
Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
CA3127776A1
(en)
|
2019-01-30 |
2020-08-06 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
JP2022524281A
(ja)
|
2019-01-30 |
2022-05-02 |
スカラー ロック インコーポレイテッド |
TGFβのLTBP複合体特異的阻害剤およびその使用
|
JP7232925B2
(ja)
|
2019-02-15 |
2023-03-03 |
ウーシー バイオロジクス アイルランド リミテッド |
改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
|
EP3929212A4
(de)
|
2019-02-22 |
2022-11-23 |
Wuhan Yzy Biopharma Co., Ltd. |
Modifiziertes fc-fragment, dieses enthaltender antikörper und dessen verwendung
|
WO2020168555A1
(zh)
|
2019-02-22 |
2020-08-27 |
武汉友芝友生物制药有限公司 |
Cd3抗原结合片段及其应用
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
MA55529A
(fr)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
|
GB201904717D0
(en)
|
2019-04-03 |
2019-05-15 |
Univ London Queen Mary |
Treatment and diagnosis of mental disorders
|
TW202102544A
(zh)
|
2019-04-04 |
2021-01-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
CN113993885A
(zh)
|
2019-04-12 |
2022-01-28 |
格尔托公司 |
重组弹性蛋白及其生产
|
JP2022532192A
(ja)
|
2019-05-10 |
2022-07-13 |
武田薬品工業株式会社 |
抗体薬物複合体
|
EP3969472A1
(de)
|
2019-05-16 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung von typ-2-entzündung oder von mastzellenabhängiger krankheit
|
TW202100559A
(zh)
|
2019-05-21 |
2021-01-01 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
JP2022532928A
(ja)
|
2019-05-24 |
2022-07-20 |
サノフイ |
全身性硬化症を治療するための方法
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
US20230340086A1
(en)
|
2019-06-19 |
2023-10-26 |
Christopher Roland Oelkrug |
Antibody-mediated neutralization of beta-lactamases
|
GB201909393D0
(en)
|
2019-06-28 |
2019-08-14 |
Gen2 Neuroscience Ltd |
Tau epitope and binding molecules
|
US20220372137A1
(en)
|
2019-07-03 |
2022-11-24 |
Oxford Biotherapeutics Ltd |
Antibodies and methods of use
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
GB2585252A
(en)
|
2019-07-05 |
2021-01-06 |
Gen2 Neuroscience Ltd |
Tau epitope and binding molecules
|
KR20220030956A
(ko)
|
2019-07-05 |
2022-03-11 |
오노 야꾸힝 고교 가부시키가이샤 |
Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
|
CN113968910A
(zh)
|
2019-07-11 |
2022-01-25 |
武汉友芝友生物制药有限公司 |
四价对称双特异性抗体
|
CN114127106B
(zh)
|
2019-07-19 |
2024-01-12 |
神州细胞工程有限公司 |
人源化抗VEGF Fab抗体片段及其用途
|
KR20220071177A
(ko)
|
2019-07-19 |
2022-05-31 |
사이노셀테크 엘티디. |
인간화 항-vegf 단클론 항체
|
WO2021013693A1
(en)
|
2019-07-23 |
2021-01-28 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates (adcs) with nampt inhibitors
|
MX2022000988A
(es)
|
2019-07-26 |
2022-05-03 |
Amgen Inc |
Proteinas de union a antigeno anti-il13.
|
MX2022001068A
(es)
|
2019-07-26 |
2022-02-14 |
Sinocelltech Ltd |
Anticuerpo anti-il17a humanizado y uso del mismo.
|
CA3146341A1
(en)
|
2019-07-30 |
2021-02-04 |
Aaron L. Kurtzman |
Bispecific anti lrrc15 and cd3epsilun antibudies
|
JP6856183B1
(ja)
|
2019-07-30 |
2021-04-07 |
小野薬品工業株式会社 |
二重特異性抗体
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
EP4031658A1
(de)
|
2019-08-07 |
2022-07-27 |
DB Biotech, AS |
Verbesserte meerrettichperoxidase-polypeptide
|
WO2021025140A1
(ja)
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
JP2022547850A
(ja)
|
2019-09-03 |
2022-11-16 |
バイオ - テラ ソリューションズ、リミテッド |
抗tigit免疫阻害剤及び応用
|
EP4025303A1
(de)
|
2019-09-04 |
2022-07-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
|
WO2021044012A1
(en)
|
2019-09-05 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment and pronostic of acute myeloid leukemia
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
MX2022002981A
(es)
|
2019-09-10 |
2022-04-06 |
Amgen Inc |
Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
|
EP3792632A1
(de)
|
2019-09-16 |
2021-03-17 |
Vito NV |
Immuntherapiemarker
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
BR112022004863A2
(pt)
|
2019-09-19 |
2022-06-07 |
Seagen Inc |
Composição conjugado de ligante fármaco, compostos conjugado de ligante-fármaco e conector de fármaco, e, formulação farmaceuticamente aceitável
|
CN114423459A
(zh)
|
2019-09-19 |
2022-04-29 |
飞跃治疗公司 |
Dkk-1抑制剂用于治疗癌症的用途
|
JP2022549504A
(ja)
|
2019-09-26 |
2022-11-25 |
エスティーキューブ アンド カンパニー |
グリコシル化ctla-4に対して特異的な抗体およびその使用方法
|
JPWO2021060439A1
(de)
|
2019-09-26 |
2021-04-01 |
|
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
CN114929284A
(zh)
|
2019-10-04 |
2022-08-19 |
西根公司 |
喜树碱肽缀合物
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
GB201915163D0
(en)
|
2019-10-18 |
2019-12-04 |
Univ Southampton |
Cancer vaccine
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
KR20220113386A
(ko)
|
2019-11-15 |
2022-08-12 |
플라이언트 테라퓨틱스, 인크. |
인테그린의 활성화를 위한 조성물 및 방법
|
CN114929275A
(zh)
|
2019-11-22 |
2022-08-19 |
飞跃治疗公司 |
使用dkk-1抑制剂治疗癌症的方法
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
JP2023507083A
(ja)
|
2019-12-19 |
2023-02-21 |
クイデル コーポレーション |
モノクローナル抗体融合物
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
KR20220119467A
(ko)
|
2019-12-27 |
2022-08-29 |
아피메트 게엠베하 |
이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
US20230090552A1
(en)
|
2020-01-08 |
2023-03-23 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021142427A1
(en)
|
2020-01-11 |
2021-07-15 |
Scholar Rock, Inc. |
TGFβ INHIBITORS AND USE THEREOF
|
AU2021205440A1
(en)
|
2020-01-11 |
2022-09-01 |
Scholar Rock,Inc. |
TGF-beta inhibitors and use thereof
|
TWI793503B
(zh)
|
2020-01-20 |
2023-02-21 |
美商美國禮來大藥廠 |
抗IL-1β抗體
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2021152548A1
(en)
|
2020-01-30 |
2021-08-05 |
Benitah Salvador Aznar |
Combination therapy for treatment of cancer and cancer metastasis
|
CN115087668A
(zh)
|
2020-01-31 |
2022-09-20 |
奥斯瓦道·克鲁兹基金会 |
抗体、其用途、药物组合物,包括真菌感染诊断方法、真菌感染诊断试剂盒和真菌感染治疗方法
|
CN115551552A
(zh)
|
2020-02-25 |
2022-12-30 |
祐方有限公司 |
喜树碱衍生物及其缀合物
|
IL295979A
(en)
|
2020-03-06 |
2022-10-01 |
Ona Therapeutics S L |
Anti-cd36 antibodies and their use for cancer treatment
|
CN115315446A
(zh)
|
2020-03-06 |
2022-11-08 |
Go医疗股份有限公司 |
抗糖-cd44抗体及其用途
|
IL296241A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Compositions and methods for immunotherapy for npm1c-positive cancer
|
WO2021180821A2
(en)
|
2020-03-10 |
2021-09-16 |
Tiziana Life Sciences Plc |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
US20230146593A1
(en)
|
2020-03-12 |
2023-05-11 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecific antibodies binding to cds x cancer cell and tnf alpha or il-6 inhibitor
|
KR20220155338A
(ko)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
뮤신 17에 대한 항체 및 이의 용도
|
US20230192833A1
(en)
|
2020-03-20 |
2023-06-22 |
Centre National De La Recherche (Cnrs) |
New anti-VEGFC antibodies and uses thereof
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
CA3173263A1
(en)
|
2020-03-30 |
2021-10-07 |
Yasuhiro Matsumura |
Antibody drug conjugate
|
WO2021197340A1
(zh)
|
2020-03-31 |
2021-10-07 |
百奥泰生物制药股份有限公司 |
用于治疗冠状病毒的抗体、融合蛋白及其应用
|
IL297167A
(en)
|
2020-04-10 |
2022-12-01 |
Seagen Inc |
Charging variant connectors
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
IL297290A
(en)
|
2020-04-17 |
2022-12-01 |
Zoetis Services Llc |
Feline antibody variants
|
US20230242635A1
(en)
|
2020-04-17 |
2023-08-03 |
Zoetis Services Llc |
Canine antibody variants
|
GB202005779D0
(en)
|
2020-04-21 |
2020-06-03 |
Scancell Ltd |
Anti-tumour immune responses
|
MX2022013455A
(es)
|
2020-04-28 |
2022-11-16 |
Sinocelltech Ltd |
Molecula truncada en el dominio extracelular de tgfbr2, proteina de fusion de molecula truncada en el dominio extracelular de tgfbr2 y anticuerpo anti-egfr, y uso antitumoral de la proteina de fusion.
|
US20210340586A1
(en)
*
|
2020-04-30 |
2021-11-04 |
Sutro Biopharma, Inc. |
Methods of Producing Full-Length Antibodies Using E. coli
|
EP3909601A1
(de)
|
2020-05-11 |
2021-11-17 |
LeukoCom GmbH |
Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
JP7352040B2
(ja)
|
2020-05-22 |
2023-09-27 |
フィロジェン エッセ.ピー.アー. |
脳腫瘍の治療のためのTNFα免疫コンジュゲート療法
|
JP2023527972A
(ja)
|
2020-05-29 |
2023-07-03 |
アムジエン・インコーポレーテツド |
Cd33及びcd3に結合する二重特異性コンストラクトの有害作用軽減投与
|
EP3919062A1
(de)
|
2020-06-02 |
2021-12-08 |
Institut Gustave-Roussy |
Modulatoren von purinergischen rezeptoren und verwandte immunkontrollpunkte zur behandlung von akutem atemnotsyndrom
|
EP4157288A2
(de)
|
2020-06-02 |
2023-04-05 |
Institut Gustave-Roussy |
Modulatoren von purinergen rezeptoren und damit verbundener immuncheckpoint zur behandlung von akutem atemnotsyndrom
|
CN113754766A
(zh)
|
2020-06-02 |
2021-12-07 |
明慧医药(上海)有限公司 |
抗b7-h3抗体及其制备和应用
|
WO2021255189A1
(en)
|
2020-06-17 |
2021-12-23 |
Tiziana Life Sciences, Plc |
Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
|
EP4168006A1
(de)
|
2020-06-18 |
2023-04-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neue strategie zur behandlung von bauchspeicheldrüsenkrebs
|
EP4172193A1
(de)
|
2020-06-29 |
2023-05-03 |
Zoetis Services LLC |
Katzenantikörpervarianten zur verbesserung der stabilität
|
EP3933035A1
(de)
|
2020-07-03 |
2022-01-05 |
Aarhus Universitet |
Zusammensetzungen mit extrazellulären vesikeln und sting-stimulatorischen mitteln
|
JP2023535792A
(ja)
|
2020-07-30 |
2023-08-21 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
コロナウイルス治療のための抗cd3抗体
|
WO2022031978A1
(en)
|
2020-08-06 |
2022-02-10 |
Bioverativ Usa Inc. |
Inflammatory cytokines and fatigue in subject with a complement mediated disease
|
WO2022028608A1
(zh)
|
2020-08-07 |
2022-02-10 |
百奥泰生物制药股份有限公司 |
抗pd-l1抗体及其应用
|
CA3194792A1
(en)
|
2020-09-15 |
2022-03-24 |
Bayer Aktiengesellschaft |
Novel anti-a2ap antibodies and uses thereof
|
TW202229337A
(zh)
|
2020-09-28 |
2022-08-01 |
美商碩騰服務公司 |
犬抗體變異體
|
PE20240110A1
(es)
|
2020-09-29 |
2024-01-22 |
Zoetis Services Llc |
Variantes de anticuerpos felinos
|
IL300314A
(en)
|
2020-10-08 |
2023-04-01 |
Affimed Gmbh |
Coupling materials with triple specificity
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
EP4229081A1
(de)
|
2020-10-15 |
2023-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
|
CA3191224A1
(en)
|
2020-10-16 |
2022-04-21 |
Shenda GU |
Multispecific binding compounds that bind to pd-l1
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
BR112023008670A2
(pt)
|
2020-11-06 |
2024-02-06 |
Amgen Inc |
Construtos polipeptídicos ligados à cd3
|
US20240067728A1
(en)
|
2020-11-06 |
2024-02-29 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
JP2023547662A
(ja)
|
2020-11-06 |
2023-11-13 |
アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cldn6及びcd3に選択的に結合するポリペプチド構築物
|
EP4240494A1
(de)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Anti-cd19-mittel und auf b-zellen abzielende kombinationstherapie zur behandlung von b-zell-malignomen
|
AU2021374839A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2022097117A1
(en)
|
2020-11-09 |
2022-05-12 |
Takeda Pharmaceutical Company Ltd. |
Antibody drug conjugates
|
WO2022109313A1
(en)
|
2020-11-20 |
2022-05-27 |
Zoetis Services Llc |
Bovine antibody variants
|
GB202018395D0
(en)
|
2020-11-23 |
2021-01-06 |
Scancell Ltd |
Immunotherapy
|
WO2022124247A1
(ja)
|
2020-12-09 |
2022-06-16 |
国立大学法人 東京医科歯科大学 |
前頭側頭葉変性症の予防又は治療剤
|
AU2021403010A1
(en)
|
2020-12-16 |
2023-07-13 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
US20220281914A1
(en)
|
2020-12-18 |
2022-09-08 |
Kiniksa Pharmaceuticals, Ltd. |
Protein compositions and methods for producing and using the same
|
CN116547298A
(zh)
|
2020-12-18 |
2023-08-04 |
硕腾服务有限责任公司 |
猫抗体恒定区中的突变
|
US20240092892A1
(en)
|
2020-12-30 |
2024-03-21 |
Bio-Thera Solutions, Ltd. |
Anti-cldn18.2 antibody, and preparation method therefor and use thereof
|
US20240115721A1
(en)
|
2021-01-13 |
2024-04-11 |
Memorial Sloan Kettering Cancer Center |
Anti-dll3 antibody-drug conjugate
|
KR20230146521A
(ko)
|
2021-01-13 |
2023-10-19 |
메모리얼 슬로안 케터링 캔서 센터 |
항체-피롤로벤조디아제핀 유도체 접합체
|
CN114763381A
(zh)
|
2021-01-13 |
2022-07-19 |
博生吉医药科技(苏州)有限公司 |
B7-h3嵌合抗原受体修饰的t细胞及其应用
|
BR112023014128A2
(pt)
|
2021-01-15 |
2023-10-31 |
Seagen Inc |
Conjugados de anticorpo-fármaco imunomodulatórios
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
EP4281079A1
(de)
|
2021-01-22 |
2023-11-29 |
Royal College of Surgeons in Ireland |
Behandlung von coronavirus
|
CN116802205A
(zh)
|
2021-01-28 |
2023-09-22 |
硕腾服务有限责任公司 |
犬抗体恒定区中的突变
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
WO2022170002A1
(en)
|
2021-02-03 |
2022-08-11 |
Seagen Inc. |
Immunostimulatory compounds and conjugates
|
CA3211686A1
(en)
|
2021-02-26 |
2022-09-01 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
KR20230165212A
(ko)
|
2021-03-02 |
2023-12-05 |
다나-파버 캔서 인스티튜트 인크. |
적혈구 장애의 치료 방법
|
EP4301782A1
(de)
|
2021-03-05 |
2024-01-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44-antikörper und deren verwendungen
|
CA3208011A1
(en)
|
2021-03-17 |
2022-09-22 |
Sarah Harris |
Methods of treating atopic dermatitis with anti il-13 antibodies
|
AU2022238571A1
(en)
|
2021-03-18 |
2023-09-14 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
TW202300179A
(zh)
|
2021-03-18 |
2023-01-01 |
美商西根公司 |
內化的生物活性化合物偶聯物選擇性釋放藥物
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
IL307233A
(en)
|
2021-03-30 |
2023-11-01 |
Bayer Ag |
Anti-SEMA3A antibodies and uses thereof
|
EP4313296A1
(de)
|
2021-03-31 |
2024-02-07 |
Bioverativ USA Inc. |
Reduzierung von chirurgieassoziierter hämolyse bei patienten mit kalter agglutininkrankheit
|
EP4314068A1
(de)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antikörper gegen gespaltenes cdcp1 und verwendungen davon
|
AR125290A1
(es)
|
2021-04-02 |
2023-07-05 |
Amgen Inc |
Construcciones de unión a mageb2
|
CN117440798A
(zh)
|
2021-04-12 |
2024-01-23 |
Acm 生物实验室私人有限公司 |
包含可溶性被包封多核苷酸和可电离的脂质的聚合物囊泡及其制备方法和用途
|
WO2022221409A1
(en)
|
2021-04-14 |
2022-10-20 |
Villaris Therapeutics, Inc. |
Anti-cd122 antibodies and uses thereof
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
EP4322937A1
(de)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Neues verfahren zur verbesserung der antitumoraktivität von makrophagen
|
WO2022221767A1
(en)
|
2021-04-16 |
2022-10-20 |
Tiziana Life Sciences Plc |
Subcutaneous administration of antibodies for the treatment of disease
|
KR20230171980A
(ko)
|
2021-04-20 |
2023-12-21 |
씨젠 인크. |
항체 의존성 세포 독성의 조절
|
US20220372168A1
(en)
|
2021-05-04 |
2022-11-24 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
EP4334358A1
(de)
|
2021-05-06 |
2024-03-13 |
Amgen Research (Munich) GmbH |
Cd20 und cd22 zielende antigenbindende moleküle zur verwendung bei proliferativen erkrankungen
|
CA3221398A1
(en)
|
2021-05-28 |
2022-12-01 |
Seagen Inc. |
Anthracycline antibody conjugates
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
CA3221555A1
(en)
|
2021-06-23 |
2022-12-29 |
Kimberly LONG |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
IL309405A
(en)
|
2021-06-29 |
2024-02-01 |
Seagen Inc |
Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
|
WO2023288267A1
(en)
|
2021-07-14 |
2023-01-19 |
2Seventy Bio, Inc. |
Engineered t cell receptors fused to binding domains from antibodies
|
WO2023285620A2
(en)
|
2021-07-14 |
2023-01-19 |
Alchemab Therapeutics Ltd. |
Compositions and methods for targeting viral proteins
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
WO2023007472A1
(en)
|
2021-07-30 |
2023-02-02 |
ONA Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
WO2023014863A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
CN115702931A
(zh)
|
2021-08-06 |
2023-02-17 |
百奥泰生物制药股份有限公司 |
抗pd-l1/cd47双特异抗体在治疗疾病中的应用
|
AU2022335718A1
(en)
|
2021-08-26 |
2024-03-28 |
Glycanostics S.R.O |
Glycoprotein biomarkers for diagnosing cancer
|
AU2022340907A1
(en)
|
2021-09-02 |
2024-03-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Anti-cecam6 antibodies with reduced side-effects
|
TW202325733A
(zh)
|
2021-09-03 |
2023-07-01 |
美商Go治療公司 |
抗醣化-lamp1抗體及其用途
|
CA3230934A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2023039249A1
(en)
|
2021-09-10 |
2023-03-16 |
Leap Therapeutics, Inc. |
Combination therapy
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
WO2023044094A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023044280A1
(en)
|
2021-09-20 |
2023-03-23 |
Eli Lilly And Company |
Anti-il-1-beta antibodies
|
WO2023057484A1
(en)
|
2021-10-06 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
AU2022365121A1
(en)
|
2021-10-14 |
2024-04-18 |
The Brigham And Women's Hospital, Inc. |
Methods of suppressing microglial activation
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
WO2023086835A1
(en)
|
2021-11-09 |
2023-05-19 |
Sensei Biotherapeutics, Inc. |
Anti-vista antibodies and uses thereof
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
GB202117928D0
(en)
|
2021-12-11 |
2022-01-26 |
Cancer Research Tech Ltd |
Immunotherapy for cancer
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2023170434A1
(en)
|
2022-03-11 |
2023-09-14 |
Macomics Limited |
Compositions and methods for modulation of macrophage activity
|
WO2023178289A2
(en)
|
2022-03-17 |
2023-09-21 |
Seagen Inc. |
Camptothecin conjugates
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023245048A1
(en)
|
2022-06-15 |
2023-12-21 |
Bioverativ Usa Inc. |
Anti-complement c1s antibody formulation
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2023250507A1
(en)
|
2022-06-24 |
2023-12-28 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases
|
WO2024003114A1
(en)
|
2022-06-29 |
2024-01-04 |
Actome Gmbh |
Detection of biomolecules in single cells
|
WO2024003380A1
(en)
|
2022-06-30 |
2024-01-04 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
|
WO2024015463A1
(en)
|
2022-07-12 |
2024-01-18 |
Leap Therapeutics, Inc. |
Combination therapy
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
US20240108744A1
(en)
|
2022-07-27 |
2024-04-04 |
Mediboston Limited |
Auristatin derivatives and conjugates thereof
|
WO2024030982A2
(en)
|
2022-08-02 |
2024-02-08 |
Diadem Spa |
Device for detection and prognostic assessment of neurodegenerative disorders
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
EP4321522A1
(de)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Zytotoxische verbindungen und konjugate davon
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
WO2024044687A1
(en)
|
2022-08-26 |
2024-02-29 |
Valo Health, Inc. |
Biomarker combinations for prognosis and management of diabetic retinopathy
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
US20240101691A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|